[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1157
1. Hadley G, Derry S, Moore RA: Imiquimod for actinic keratosis: systematic review and meta-analysis. J Invest Dermatol; 2006 Jun;126(6):1251-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod for actinic keratosis: systematic review and meta-analysis.
  • Benefit and harm associated with treating actinic keratosis (AK) with the immune response modifier imiquimod was assessed using published randomized-controlled trials.
  • Complete clearance occurred in 50% of patients treated with imiquimod, compared to 5% treated with vehicle, and the number needed to treat (NNT) for one patient to have their keratosis completely cleared after 12-16 weeks was 2.2 (95% confidence interval 2.0-2.5).
  • Imiquimod 5% cream was effective in the treatment of AK, preventing potential development of squamous cell carcinoma.
  • [MeSH-major] Aminoquinolines / adverse effects. Antineoplastic Agents / adverse effects. Carcinoma in Situ / drug therapy. Carcinoma, Squamous Cell / drug therapy. Keratosis / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16557235.001).
  • [ISSN] 0022-202X
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Ointments; 99011-02-6 / imiquimod
  • [Number-of-references] 27
  •  go-up   go-down


2. Werschler WP: Considerations for use of Fluorouracil cream 0.5% for the treatment of actinic keratosis in elderly patients. J Clin Aesthet Dermatol; 2008 Jul;1(2):22-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Considerations for use of Fluorouracil cream 0.5% for the treatment of actinic keratosis in elderly patients.
  • Actinic keratosis (AK), the initial lesion in a disease continuum that may progress to squamous cell carcinoma, often begins with ultraviolet B light-induced photo damage and increases in prevalence with age.
  • Topical 5-fluorouracil (5-FU) for the treatment of widespread multiple AK lesions has cure rates of more than 90 percent.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21103319.001).
  • [ISSN] 1941-2789
  • [Journal-full-title] The Journal of clinical and aesthetic dermatology
  • [ISO-abbreviation] J Clin Aesthet Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2989823
  •  go-up   go-down


3. Smits T, Robles CA, van Erp PE, van de Kerkhof PC, Gerritsen MJ: Correlation between macroscopic fluorescence and protoporphyrin IX content in psoriasis and actinic keratosis following application of aminolevulinic acid. J Invest Dermatol; 2005 Oct;125(4):833-9
MedlinePlus Health Information. consumer health - Psoriasis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between macroscopic fluorescence and protoporphyrin IX content in psoriasis and actinic keratosis following application of aminolevulinic acid.
  • In fluorescence diagnosis with 5-aminolevulinic acid (ALA)-induced porphyrins (FDAP), protoporphyrin IX (PpIX) accumulation can be macroscopically visualized.
  • In this study, PpIX accumulation is investigated in patients with psoriasis and actinic keratosis (AK) following FDAP.
  • PpIX per biopsy in lesional skin in both psoriasis and AK was significantly higher than in non-lesional skin (p < 0.05).
  • When corrected for epidermal involvement, only lesional psoriatic skin showed significantly higher PpIX levels than non-lesional skin.
  • The PpIX-ratio lesional:non-lesional skin (mean(pmol per mL)+/-SEM) was 4.12+/-0.91 in psoriasis and 1.96+/-0.24 in AK.
  • In FDAP, the ratio of lesional:non-lesional skin was 1.77+/-0.06 in psoriasis and 1.37+/-0.07 in AK.
  • [MeSH-major] Aminolevulinic Acid. Keratosis / diagnosis. Protoporphyrins / analysis. Psoriasis / diagnosis

  • Genetic Alliance. consumer health - Psoriasis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16185285.001).
  • [ISSN] 0022-202X
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protoporphyrins; 553-12-8 / protoporphyrin IX; 88755TAZ87 / Aminolevulinic Acid; 9007-49-2 / DNA
  •  go-up   go-down


Advertisement
4. Roewert-Huber J, Stockfleth E, Kerl H: Pathology and pathobiology of actinic (solar) keratosis - an update. Br J Dermatol; 2007 Dec;157 Suppl 2:18-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathology and pathobiology of actinic (solar) keratosis - an update.
  • Actinic keratosis is a UV light-induced lesion and develops mostly in fair-skinned patients being susceptible to solar damage.
  • The term actinic keratosis (AK) describes clinically ill-defined reddish to reddish-brown scaly lesions on erythematous base in areas damaged severely by sunlight.
  • Actinic keratoses (AKs) have been recognized as precursor of cancer or of precancerous lesions in the past but today they are considered as an early in situ squamous cell carcinoma (1,2) and are categorized in several classifications with subdivisions into three grades depending on the amount of atypical keratinocytes in the epidermis.(3-6) The incidence of development of AK in caucasians increases with age, proximity to the equator and outdoor occupation.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Keratosis / pathology. Neoplasms, Radiation-Induced / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18067626.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 33
  •  go-up   go-down


5. Choi KH, Kim GM, Kim SY: The keratin-14 expression in actinic keratosis and squamous cell carcinoma: is this a prognostic factor for tumor progression? Cancer Res Treat; 2010 Jun;42(2):107-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The keratin-14 expression in actinic keratosis and squamous cell carcinoma: is this a prognostic factor for tumor progression?
  • PURPOSE: Actinic keratosis (AK) is an incipient form of cutaneous squamous cell carcinoma (SCC).
  • We determined if the pattern of expression of keratin-14 (K14) is a factor for tumor progression in AK and SCC.
  • Among the 16 patients, 4 were diagnosed with both SCC and AK at the same site, but AK developed first and SCC developed subsequently.
  • Thus, SCC may have evolved from AK.
  • The other 12 patients were only diagnosed with AK.
  • RESULTS: In all of the AK and SCC tissues, basement membranes showed positive staining for K14.
  • However, strong reactivities were shown in the spinous and granular layers and focuses of dermal invasion in the SCC tissues developed from AK.
  • Two and 3 of the 12 AK cases had moderately positive reactions for K14 in the spinous and granular layers, respectively.
  • Two of the 12 AK cases had weak-to-moderate positive reactions in the basal, spinous, and horny layers for p16(INK4a).
  • CONCLUSION: The results of our study advance our understanding of the pathogenesis of SCC developing from AK.
  • The results also indicate a differential role in the control of K14 in normal epithelia, AK, and SCC.
  • K14 expression in the spinous and granular layers may be a prognostic factor for tumor progression of AK.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dermatol Clin. 1999 Jul;17(3):667-89, x [10410866.001]
  • [Cites] J Clin Pathol. 1997 Dec;50(12):1032-3 [9516889.001]
  • [Cites] Int J Cancer. 1997 Feb 20;74(1):26-30 [9036865.001]
  • [Cites] J Oral Pathol Med. 1996 Jul;25(6):293-301 [8887072.001]
  • [Cites] Growth Factors. 1995;12(2):87-97 [8679251.001]
  • [Cites] Dermatol Surg. 1995 Feb;21(2):184 [7894943.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1994 Sep;30B(5):305-11 [7535610.001]
  • [Cites] Annu Rev Biochem. 1994;63:345-82 [7979242.001]
  • [Cites] Lancet. 1988 Apr 9;1(8589):795-7 [2895318.001]
  • [Cites] J Dermatol Surg Oncol. 1985 May;11(5):518-22 [3998264.001]
  • [Cites] Cell. 1982 Nov;31(1):11-24 [6186379.001]
  • [Cites] Clin Dermatol. 2004 May-Jun;22(3):189-96 [15262304.001]
  • [Cites] Br J Dermatol. 2003 Nov;149(5):1006-12 [14632806.001]
  • [Cites] Arch Dermatol. 2003 Jan;139(1):66-70 [12533168.001]
  • [Cites] Histopathology. 2002 May;40(5):403-39 [12010363.001]
  • [Cites] Br J Dermatol. 2001 Aug;145(2):223-8 [11531783.001]
  • [Cites] Histopathology. 2001 Jul;39(1):9-16 [11454039.001]
  • [Cites] Int J Cancer. 2001 Apr 15;92(2):276-84 [11291057.001]
  • [Cites] South Med J. 2000 Jul;93(7):650-5 [10923948.001]
  • [Cites] J Am Acad Dermatol. 2000 Jan;42(1 Pt 2):23-4 [10607353.001]
  • (PMID = 20622965.001).
  • [ISSN] 2005-9256
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2901083
  • [Keywords] NOTNLM ; Actinic / Carcinoma / Keratin-14 / Keratosis / Squamous cell / p16INK4a
  •  go-up   go-down


6. Berner A: [Actinic keratosis and development of cutaneous squamous cell carcinoma]. Tidsskr Nor Laegeforen; 2005 Jun 16;125(12):1653-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Actinic keratosis and development of cutaneous squamous cell carcinoma].
  • [Transliterated title] Aktinisk keratose og utvikling av plateepitelkarsinom i hud.
  • BACKGROUND: Actinic keratosis is a common sun-induced skin disease.
  • For many years there has been a great deal of discussion of the term used for the disease and of its classification.
  • Recent molecular studies indicate an association between actinic keratosis and squamous cell carcinoma.
  • MATERIAL AND METHODS: Review of recent reports on histological, molecular, biochemical and clinical findings in actinic keratosis and cutaneous squamous cell carcinoma.
  • RESULTS AND INTERPRETATION: The morphology of atypical cells in both actinic keratosis and squamous cell carcinoma is identical.
  • The risk of progression to squamous cell carcinoma is minimal, but up to 60% of squamous cell carcinoma cases begin as actinic keratosis.
  • Regression of actinic keratosis occurs when sun exposure is decreased.
  • Examination of possible chromosome aberrations and gene mutations in both actinic keratosis and squamous cell carcinoma reveals similar patterns, including the same mutation in the tumour suppressor gene TP53.
  • Recent studies indicate that actinic keratosis is the earliest manifestation of a potentially malignant disease similar to carcinoma in situ in cervix uteri.
  • Thus, actinic keratosis requires careful diagnosis and follow up.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Keratosis / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Carcinoma in Situ / pathology. Cervical Intraepithelial Neoplasia / pathology. Female. Humans. Male. Neoplasms, Radiation-Induced / pathology. Precancerous Conditions / pathology. Ultraviolet Rays / adverse effects

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15976832.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Norway
  • [Number-of-references] 21
  •  go-up   go-down


7. Angell-Petersen E, Sørensen R, Warloe T, Soler AM, Moan J, Peng Q, Giercksky KE: Porphyrin formation in actinic keratosis and basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Invest Dermatol; 2006 Feb;126(2):265-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Porphyrin formation in actinic keratosis and basal cell carcinoma after topical application of methyl 5-aminolevulinate.
  • Photodynamic therapy using topical methyl 5-aminolevulinate (MAL) is a new treatment modality for basal cell carcinoma (BCC) and actinic keratosis (AK).
  • MAL induces endogenous porphyrins, which act as photosensitizers.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Carcinoma, Basal Cell / drug therapy. Keratosis / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / biosynthesis. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16374471.001).
  • [ISSN] 0022-202X
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ointments; 0 / Photosensitizing Agents; 0 / Porphyrins; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


8. Berman B, Amini S, Valins W, Block S: Pharmacotherapy of actinic keratosis. Expert Opin Pharmacother; 2009 Dec;10(18):3015-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacotherapy of actinic keratosis.
  • Actinic keratosis (AK) represents the initial intraepidermal manifestation of abnormal keratinocyte proliferation with the potential of progression to squamous cell carcinoma (SCC).
  • Owing to difficulties in predicting which AK will progress to SCC, the general rule is to treat all AKs.
  • [MeSH-major] Keratosis, Actinic / drug therapy

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19925043.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 179
  •  go-up   go-down


9. Gold MH, Nestor MS: Current treatments of actinic keratosis. J Drugs Dermatol; 2006 Feb;5(2 Suppl):17-25
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current treatments of actinic keratosis.
  • Actinic keratosis (AK) lesions should be treated because they may evolve into lesions clinically indistinguishable from those of invasive squamous cell carcinoma which require expensive therapy.
  • Treatment options for AK include cryosurgery, curettage and excisional surgery, dermabrasion, chemical peels, laser resurfacing, 5-fluorouracil (5-FU), imiquimod, diclofenac, and tretinoin, each with advantages and limitations.
  • Clinical trial results show that photodynamic therapy (PDT) with 5-aminolevulinic acid (ALA) is an effective and safe treatment of nonhypertrophic AK lesions of the scalp and face.
  • ALA incubation times of 1-hour make ALA PDT a practical procedure for the treatment of AK lesions.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Keratosis / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use. Skin Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16485877.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  • [Number-of-references] 76
  •  go-up   go-down


10. Higa GM, Kovach RF, Abraham J: Actinic keratosis and capecitabine therapy. J Oncol Pharm Pract; 2005 Dec;11(4):151-3
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Actinic keratosis and capecitabine therapy.
  • Topical application of 5-fluorouracil (5-FU) is one of the most effective clinical strategies available to treat actinic keratosis (AK).
  • We report a case of a typical flare of AK in a woman treated with capecitabine for advanced breast cancer.
  • [MeSH-major] Deoxycytidine / analogs & derivatives. Keratosis / chemically induced

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16595067.001).
  • [ISSN] 1078-1552
  • [Journal-full-title] Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • [ISO-abbreviation] J Oncol Pharm Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Peris K, Micantonio T, Piccolo D, Fargnoli MC: Dermoscopic features of actinic keratosis. J Dtsch Dermatol Ges; 2007 Nov;5(11):970-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermoscopic features of actinic keratosis.
  • Actinic keratosis (AK) is a keratinocytic neoplasm that typically develops on sun-damaged skin of elderly individuals.
  • Only a few reports so far have described the dermoscopic diagnostic features of AK, mainly focusing on facial non-pigmented AKs.
  • A typical feature of facial non-pigmented AK is a composite pattern named "strawberry pattern", characterized by a background erythema/red pseudonetwork consisting of unfocused, large vessels located between the hair follicles, associated with prominent follicular openings surrounded by a white halo.
  • Dermoscopic characteristics of pigmented AK on the face include multiple slate-gray to dark-brown dots and globules around the follicular ostia, annular-granular pattern and brown to gray pseudonetwork.
  • Recognizing specific dermoscopic features of AK can be useful in guiding the clinician in the differential diagnosis of AK with melanocytic skin lesions such as LM and non-melanocytic lesions.
  • Histopathologic examination should be performed whenever clinical and/or dermoscopic differential diagnosis is inconclusive.
  • [MeSH-major] Dermoscopy / methods. Keratosis / pathology. Photosensitivity Disorders / pathology. Skin / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17908179.001).
  • [ISSN] 1610-0387
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] eng; ger
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 20
  •  go-up   go-down


12. Zalaudek I, Giacomel J, Argenziano G, Hofmann-Wellenhof R, Micantonio T, Di Stefani A, Oliviero M, Rabinovitz H, Soyer HP, Peris K: Dermoscopy of facial nonpigmented actinic keratosis. Br J Dermatol; 2006 Nov;155(5):951-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermoscopy of facial nonpigmented actinic keratosis.
  • BACKGROUND: The accuracy of clinical diagnosis of nonpigmented, facial actinic keratosis (AK) is often suboptimal, even for experienced clinicians.
  • OBJECTIVES: To investigate the dermoscopic features of nonpigmented AK located on the head/neck that may assist the clinical diagnosis.
  • RESULTS: Four essential dermoscopic features were observed in facial AK: (i) erythema, revealing a marked pink-to-red 'pseudonetwork' surrounding the hair follicles (95%);.
  • CONCLUSIONS: A dermoscopic model of 'strawberry' pattern is presented, which may prove helpful in the in vivo diagnosis of nonpigmented, facial AK.
  • [MeSH-major] Dermoscopy / methods. Facial Dermatoses / diagnosis. Keratosis / diagnosis. Photosensitivity Disorders / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17034524.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


13. Helbig D, Grabbe S, Jansen T: [Keratosis follicularis spinulosa decalvans]. Hautarzt; 2008 Jan;59(1):46-9
MedlinePlus Health Information. consumer health - Steroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Keratosis follicularis spinulosa decalvans].
  • [Transliterated title] Keratosis follicularis spinulosa decalvans.
  • Keratosis follicularis spinulosa decalvans is a rare, X-linked disorder of keratinization of the hair follicle with inflammation and atrophy associated with corneal dystrophy and other symptoms.
  • The girl had thinning of the eyelashes and eyebrows as well as scarring alopecia of the scalp as additional features of the disease.
  • [MeSH-major] Darier Disease / diagnosis. Darier Disease / drug therapy. Genetic Diseases, X-Linked / diagnosis. Genetic Diseases, X-Linked / drug therapy. Glucocorticoids / therapeutic use

  • Genetic Alliance. consumer health - Darier Disease.
  • Genetic Alliance. consumer health - Keratosis follicularis spinulosa decalvans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Dermatol. 1985 Sep;121(9):1167-74 [4037843.001]
  • [Cites] J Med Genet. 1992 Jan;29(1):36-40 [1552542.001]
  • [Cites] Am J Hum Genet. 1992 Apr;50(4):801-7 [1550124.001]
  • [Cites] Hautarzt. 1993 Aug;44(8):529-34 [8376108.001]
  • [Cites] Hum Genet. 2002 Sep;111(3):235-41 [12215835.001]
  • [Cites] J Med Genet. 1995 Sep;32(9):736-9 [8544196.001]
  • [Cites] Arch Dermatol. 1978 May;114(5):761-4 [646399.001]
  • [Cites] J Med Genet. 1998 Apr;35(4):336-7 [9598732.001]
  • [Cites] Dermatology. 1992;184(2):133-6 [1498376.001]
  • [Cites] Hautarzt. 1999 Apr;50(4):295-8 [10354925.001]
  • [Cites] Med Cutan Ibero Lat Am. 1985;13(2):175-81 [3900603.001]
  • [Cites] J Pediatr. 1969 Sep;75(3):436-42 [5804190.001]
  • [Cites] Pediatr Dermatol. 2004 Jan-Feb;21(1):14-7 [14871319.001]
  • [Cites] J Am Acad Dermatol. 2002 Nov;47(5 Suppl):S275-8 [12399750.001]
  • [Cites] J Pediatr. 1974 Apr;84(4):564-7 [4834251.001]
  • [Cites] Ann Dermatol Venereol. 1978 Apr;105(4):433-8 [686619.001]
  • [Cites] Australas J Dermatol. 2005 Nov;46(4):257-60 [16197427.001]
  • [Cites] Hum Genet. 1997 Oct;100(5-6):520-4 [9341865.001]
  • (PMID = 17551700.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Dermatologic Agents; 0 / Glucocorticoids
  •  go-up   go-down


14. Arnold AW, Buechner SA: [Keratosis pilaris and keratosis pilaris atrophicans faciei]. J Dtsch Dermatol Ges; 2006 Apr;4(4):319-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Keratosis pilaris and keratosis pilaris atrophicans faciei].
  • [Transliterated title] Keratosis pilaris und Keratosis pilaris atrophicans faciei.
  • Keratosis pilaris and ulerythema ophryogenes (keratosis pilaris atrophicans faciei) are hereditary disorders with altered follicular keratinization that show follicular, horny papules surrounded by an erythematous halo.
  • Ulerythema ophryogenes is an uncommon variant of keratosis pilaris characterized by erythematous follicular papules of the eyebrows and cheeks followed by a gradual loss of hair.
  • On the background of 15-year-old boy who presented with keratosis pilaris and ulerythema ophryogenes, we discuss the various clinical manifestations of keratosis pilaris.
  • [MeSH-major] Alopecia / diagnosis. Alopecia / therapy. Keratosis / diagnosis. Keratosis / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16638061.001).
  • [ISSN] 1610-0379
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 19
  •  go-up   go-down


15. Kaptanoglu AF, Kutluay L: Keratoacanthoma developing in previous cryotherapy site for solar keratosis. J Eur Acad Dermatol Venereol; 2006 Feb;20(2):197-8
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Keratoacanthoma developing in previous cryotherapy site for solar keratosis.
  • We report a rare case of keratoacanthoma arising in the site of cryotherapy applied for solar keratosis.
  • [MeSH-major] Cryotherapy / adverse effects. Keratoacanthoma / diagnosis. Skin Diseases / diagnosis
  • [MeSH-minor] Cicatrix / pathology. Diagnosis, Differential. Humans. Keratosis / surgery. Male. Middle Aged. Nose / pathology. Sunlight

  • Genetic Alliance. consumer health - Keratoacanthoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16441631.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


16. Kozyreva ON, Konnikov N: The incidence of non-melanoma skin cancer after a single field treatment with aminolevulinic acid and blue light photodynamic therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e14646

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Study population included immunocompetent pts with history of NMSC, multiple actinic keratosis (AKs), and moderate to severe dermatoheliosis (DH).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964235.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Jirakulaporn T, Mathew J, Lindgren BR, Dudek AZ: Efficacy of capecitabine in secondary prevention of skin cancer in solid organ-transplanted recipients (OTR). J Clin Oncol; 2009 May 20;27(15_suppl):1519

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Topical 5% 5-FU has been used to successfully treat squamous cell carcinoma (SCC) in situ and actinic keratosis (AK).
  • Cumulative incidence rates of SCC, BCC, and AK before and after treatment were scored and statistically compared for each patient with a non-parametric Wilcoxon signed-rank test.
  • Mean incidence rates of SCC, BCC, and AK before treatment were 0.45, 0.05, and 4.99 lesions per month, respectively.
  • Mean incidence rates of SCC, BCC, and AK after treatment were 0.22, 0.04, and 2.80 lesions per month, respectively.
  • The differences in incidence rates of SCC, BCC, and AK before and after treatment were 0.24, 0.02, and 2.08 lesions per month with p value of 0.048, 0.844, and 0.151, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964327.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Walsh SN, Hurt MA, Santa Cruz DJ: Psoriasiform keratosis. Am J Dermatopathol; 2007 Apr;29(2):137-40
MedlinePlus Health Information. consumer health - Psoriasis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Psoriasiform keratosis.
  • Presented herein are 18 cases of erythematous, scaly papules or plaques with microscopic features of both seborrheic keratosis and psoriasis.
  • There was, however, no known clinical diagnosis of psoriasis in any patient, neither at initial presentation nor on follow-up examination.
  • The mean age at diagnosis was 66.8 years.
  • The most common diagnoses, clinically, were seborrheic keratosis, followed by basal cell carcinoma, Bowen's disease, actinic (solar) keratosis, and squamous cell carcinoma, among others.
  • Histologic examination revealed irregular verrucous epidermal acanthosis, with hyperkeratosis, parakeratosis, hypergranulosis, and intracorneal collections of neutrophils, often in alternating tiers.
  • We have coined the term psoriasiform keratosis as a provisional appellation until the nature of these lesions is determined more definitively.
  • It is unclear whether a psoriasiform keratosis is a rudimentary manifestation of psoriasis or a lesion sui generis.
  • [MeSH-major] Keratosis, Seborrheic / pathology. Psoriasis / pathology. Skin / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Lichenoid Eruptions / pathology. Lymphocytes / pathology. Male. Middle Aged. Neutrophils / pathology. Prospective Studies. Terminology as Topic. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414434.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Barrera MV, Herrera E: [Topical chemotherapy for actinic keratosis and nonmelanoma skin cancer: current options and future perspectives]. Actas Dermosifiliogr; 2007 Oct;98(8):556-62
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Topical chemotherapy for actinic keratosis and nonmelanoma skin cancer: current options and future perspectives].
  • [Transliterated title] Tratamiento quimioterápico tópico de la queratosis actínica y el cáncer cutáneo no melanoma: situación actual y perspectivas.
  • Actinic keratosis is currently considered not to be a precursor of squamous cell carcinoma but, rather, an initial stage of the disease.
  • [MeSH-major] Keratosis / drug therapy. Keratosis / etiology. Skin Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17919432.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 33
  •  go-up   go-down


20. Berman B, Villa AM, Ramirez CC: Mechanisms of action of new treatment modalities for actinic keratosis. J Drugs Dermatol; 2006 Feb;5(2):167-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanisms of action of new treatment modalities for actinic keratosis.
  • Actinic keratosis (AK) constitutes the initial lesion in a disease continuum that can progress to invasive squamous cell carcinoma (SCC).
  • In this article, we describe the mechanisms of action, tolerability, and efficacy of the most frequently used chemopreventative, chemotherapeutic, destructive, and novel immunologic methods for the control and treatment of actinic keratoses.
  • [MeSH-major] Aminoquinolines / therapeutic use. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Antimetabolites / therapeutic use. Antineoplastic Agents / therapeutic use. Diclofenac / therapeutic use. Fluorouracil / therapeutic use. Keratosis / drug therapy. Photochemotherapy / methods

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16485885.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antimetabolites; 0 / Antineoplastic Agents; 0 / Teratogens; 144O8QL0L1 / Diclofenac; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil
  • [Number-of-references] 46
  •  go-up   go-down


21. Stockfleth E: Topical management of actinic keratosis and field cancerisation. G Ital Dermatol Venereol; 2009 Aug;144(4):459-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical management of actinic keratosis and field cancerisation.
  • Actinic keratosis (AK) is a squamous cell carcinoma of the epidermis in situ.
  • In around 10% of all patients with AK and in approximately 30% of patients with additional immune suppression an invasive squamous cell carcinoma of the skin is subsequently observed highlighting that AKs should be identified and treated early.
  • The hallmarks and characteristic features of non-melanoma skin cancer have been defined histologically: histopathology allows the differentiation based on a small tissue sample and remains the gold standard for diagnosis.
  • For all therapies the objective is to cure lesions, both clinically and histologically, by the destruction of mutated keratinocytes and to reduce the numbers of AK lesions with the minimum of pain, scarring and recurrence.
  • Recurrence of a lesion (which by definition affects the same site) is often the result of incomplete removal of clinically apparent AK lesions after treatment or the presence of subclinical lesions that were not identified and removed.
  • AK lesions can be treated individually or, if the lesions are numerous in an area of sun-damaged skin the whole area should be treated to remove subclinical lesions as well as those clinically visible (field-directed therapy).Overall the treatment choice is based on several factors, including location and number of lesions, growth and morphology, area of sun-damaged skin, age, lifestyle, and factors related to previous treatment or patient history.
  • [MeSH-major] Keratosis, Actinic / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19755950.001).
  • [ISSN] 0392-0488
  • [Journal-full-title] Giornale italiano di dermatologia e venereologia : organo ufficiale, Società italiana di dermatologia e sifilografia
  • [ISO-abbreviation] G Ital Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


22. Deltondo JA, Helm KF: Actinic keratosis: precancer, squamous cell carcinoma, or marker of field cancerization? G Ital Dermatol Venereol; 2009 Aug;144(4):441-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Actinic keratosis: precancer, squamous cell carcinoma, or marker of field cancerization?
  • The early detection, recognition, and progression of the actinic keratosis (AK) and its relationship with squamous cell carcinoma have long been an area of debate.
  • The role of AK as a marker for field cancerization will be here discussed.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Keratosis, Actinic / pathology. Precancerous Conditions / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19755947.001).
  • [ISSN] 0392-0488
  • [Journal-full-title] Giornale italiano di dermatologia e venereologia : organo ufficiale, Società italiana di dermatologia e sifilografia
  • [ISO-abbreviation] G Ital Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


23. Uhlenhake EE, Sangueza OP, Lee AD, Jorizzo JL: Spreading pigmented actinic keratosis: a review. J Am Acad Dermatol; 2010 Sep;63(3):499-506
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spreading pigmented actinic keratosis: a review.
  • INTRODUCTION: Spreading pigmented actinic keratosis (SPAK) is a common, but uncommonly reported or appreciated, variant of classic actinic keratosis (AK).
  • It can mimic different pigmented lesions, which may be benign (eg, solar lentigo) or malignant (eg, lentigo maligna).
  • METHODS: A literature search was performed in both PubMed and MEDLINE databases using the search terms "spreading pigmented actinic keratosis," "pigmented solar keratosis," "pigmented actinic," and "pigmented solar."
  • RESULTS: SPAK is a rarely reported lesion that can be difficult to distinguish from other benign and malignant pigmented lesions, including seborrheic keratosis, melanoma in situ (lentigo maligna type), and lentigo maligna melanoma.
  • Pathologically, the lesion resembles classic AK with increased basal melanization.
  • CONCLUSIONS: SPAK can be associated with adjacent melanoma in situ; therefore, its diagnosis merits increased suspicion for coexisting melanoma.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Hutchinson's Melanotic Freckle / pathology. Keratosis, Actinic / pathology. Precancerous Conditions / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Dermoscopy / methods. Diagnosis, Differential. Disease Progression. Female. Humans. Immunohistochemistry. Male. Neoplasm Staging. Risk Assessment

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20334953.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  •  go-up   go-down


24. Davis DA, Donahue JP, Bost JE, Horn TD: The diagnostic concordance of actinic keratosis and squamous cell carcinoma. J Cutan Pathol; 2005 Sep;32(8):546-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnostic concordance of actinic keratosis and squamous cell carcinoma.
  • Because the diagnosis of actinic keratosis (AK) and squamous cell carcinoma (SCC) is not uniform and because such terms are not consonant with the nomenclature of other human epithelial malignancies, nomenclature revisions have been attempted.
  • One hundred dermatopathologists were solicited to review 15 tissue sections representing a spectrum of varying thickness epidermal malignancy and to choose either AK or SCC as the diagnosis.
  • Among the 77 participating dermatopathologists, intraclass correlation was high for what was perceived as AK, SCC, and their differentiation.
  • Development of a two-tiered diagnostic system that retains our present diagnostic capabilities, but better fits the pathobiology of superficial epidermal malignancy is suggested.
  • The diagnostic concordance of actinic keratosis and squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Keratosis / diagnosis. Photosensitivity Disorders / diagnosis. Precancerous Conditions / diagnosis. Skin / pathology. Skin Neoplasms / diagnosis
  • [MeSH-minor] Carcinoma in Situ / classification. Carcinoma in Situ / diagnosis. Diagnosis, Differential. Humans. Reproducibility of Results

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Cutan Pathol. 2006 Sep;33(9):654; author reply 655 [16965343.001]
  • (PMID = 16115053.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


25. Lintell NA, Maguire DJ, Griffiths LR, McCabe M: Analysis of SDHD and MMP12 in an affected solar keratosis and control cohort. Adv Exp Med Biol; 2007;599:79-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of SDHD and MMP12 in an affected solar keratosis and control cohort.
  • In terms of incidence up to 40% of the Australian population over 40 years of age is thought to possess the precancerous Solar Keratosis (SK) lesion and with a small, but significant, chance of progression into SCC, understanding the genetic events that play a role in this process is essential.
  • More specifically the first aim of this project was to analyse the SDHD and MMP12 genes via Dual-Labelled Probe Real-Time PCR for copy number aberrations in an affected Solar Keratosis and control cohort.
  • The significance of this study is the contribution to the knowledge of the genetic pathways that are malformed in the progression and development of the pre-cancerous skin lesion Solar Keratosis.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. Keratosis / genetics. Matrix Metalloproteinase 12 / genetics. Skin Neoplasms / genetics. Succinate Dehydrogenase / genetics. Sunlight / adverse effects

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17727250.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / SDHD protein, human; EC 1.3.99.1 / Succinate Dehydrogenase; EC 3.4.24.65 / MMP12 protein, human; EC 3.4.24.65 / Matrix Metalloproteinase 12
  •  go-up   go-down


26. López-Tizón E, Mencía-Gutiérrez E, Garrido-Ruíz M, Gutiérrez-Díaz E, López-Ríos F: Clinicopathological study of 21 cases of eyelid actinic keratosis. Int Ophthalmol; 2009 Oct;29(5):379-84
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological study of 21 cases of eyelid actinic keratosis.
  • BACKGROUND: Actinic keratosis (AK) is an intraepidermal malignancy precursor form of cutaneous squamous cell carcinoma (SCC), which generally occurs in fair-skinned individuals with long-term sun exposure.
  • The most frequent AK type was type I (76.2%).
  • [MeSH-major] Eyelid Diseases / pathology. Keratosis, Actinic / pathology

  • MedlinePlus Health Information. consumer health - Eyelid Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Plast Surg. 2005 Apr;32(2):223-35 [15814119.001]
  • [Cites] Dermatol Surg. 2005 Jan;31(1):43-7 [15720095.001]
  • [Cites] Eur J Dermatol. 2006 Nov-Dec;16(6):599-606 [17229598.001]
  • [Cites] Am J Ophthalmol. 2006 Aug;142(2):293-7 [16876511.001]
  • [Cites] J Am Acad Dermatol. 1999 Jan;40(1):114-6 [9922027.001]
  • [Cites] J Fr Ophtalmol. 2002 Dec;25(10):1081-5 [12527837.001]
  • [Cites] J Am Acad Dermatol. 2000 Jan;42(1 Pt 2):8-10 [10607350.001]
  • [Cites] Mutat Res. 1998 Nov 9;422(1):185-90 [9920444.001]
  • [Cites] Dermatol Surg. 2006 Oct;32(10):1261-5 [17034376.001]
  • [Cites] Br J Ophthalmol. 2002 Oct;86(10):1161-5 [12234899.001]
  • [Cites] Br J Dermatol. 2003 Nov;149 Suppl 66:31-3 [14616345.001]
  • [Cites] J Fr Ophtalmol. 2003 May;26(5):534-7 [12819620.001]
  • [Cites] Br J Dermatol. 2002 Apr;146 Suppl 61:1-6 [11966724.001]
  • [Cites] Ophthalmology. 1999 Apr;106(4):746-50 [10201597.001]
  • [Cites] Arch Ophthalmol. 1995 Aug;113(8):977-8 [7639670.001]
  • [Cites] Clin Exp Ophthalmol. 2002 Feb;30(1):23-7 [11885790.001]
  • [Cites] Br J Ophthalmol. 2007 Mar;91(3):325-9 [17020898.001]
  • [Cites] Arch Dermatol. 2003 Sep;139(9):1216-7 [12975172.001]
  • [Cites] Eur J Dermatol. 2006 Jul-Aug;16(4):335-9 [16935787.001]
  • [Cites] Oncol Rep. 2004 Nov;12(5):1039-43 [15492790.001]
  • [Cites] Dermatol Surg. 2000 Aug;26(8):728-32 [10940057.001]
  • [Cites] Am Fam Physician. 1984 Jul;30(1):103-8 [6464944.001]
  • [Cites] J Am Acad Dermatol. 2000 Jan;42(1 Pt 2):11-7 [10607351.001]
  • [Cites] Clin Exp Ophthalmol. 2007 Mar;35(2):174-85 [17362462.001]
  • [Cites] J Cutan Med Surg. 2002 May-Jun;6(3):207-9 [11951126.001]
  • (PMID = 18633577.001).
  • [ISSN] 1573-2630
  • [Journal-full-title] International ophthalmology
  • [ISO-abbreviation] Int Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


27. Newman MD, Weinberg JM: Topical therapy in the treatment of actinic keratosis and basal cell carcinoma. Cutis; 2007 Apr;79(4 Suppl):18-28
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical therapy in the treatment of actinic keratosis and basal cell carcinoma.
  • Actinic keratosis (AK) is an evolving malignant cutaneous neoplasm.
  • AK also is known as solar keratosis and squamous cell carcinoma (SCC) in situ, either solar keratotic type or keratinocytic intraepidermal neoplasia.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Keratosis / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17508492.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cyclooxygenase Inhibitors; 0 / Retinoids; 0 / Tubulin Modulators
  • [Number-of-references] 44
  •  go-up   go-down


28. Warino L, Tusa M, Camacho F, Teuschler H, Fleischer AB Jr, Feldman SR: Frequency and cost of actinic keratosis treatment. Dermatol Surg; 2006 Aug;32(8):1045-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency and cost of actinic keratosis treatment.
  • BACKGROUND: Actinic keratosis (AK) is a common lesion with its highest incidence in the aged population.
  • Although treatment strategies for AK have continued to develop, the cost of such treatments has not been recently investigated.
  • PURPOSE: The purpose of this article is to determine the frequency of visits for AK, the methods used to treat AK, and the cost of the treatments used annually.
  • METHODS: Data from the Medicare Current Beneficiary Survey and National Ambulatory Medical Care Survey were used to determine the frequency of office visits for AK and the frequency of destructive procedures and topical treatment of AK.
  • RESULTS: There are an estimated 5.2 million AK visits annually, 60% of which are made by the Medicare population.
  • A total of Dollars 920 million was spent on the treatment of AK annually, 6% being spent on topical therapy, 43% on office visits, and 51% on destructive procedures.
  • CONCLUSIONS: Even though new topical therapies are evolving for the treatment of AK, destructive procedures remain the standard of care when considering frequency of use, efficacy, and cost control.
  • [MeSH-major] Costs and Cost Analysis. Keratosis / economics. Keratosis / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16918567.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


29. Tomas D, Kruslin B, Cupic H, Stanimirovic A, Bosnjak B, Lovricevic I, Belicza M: Correlation between Bcl-2 and Bax in atrophic and hypertrophic type of actinic keratosis. J Eur Acad Dermatol Venereol; 2006 Jan;20(1):51-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between Bcl-2 and Bax in atrophic and hypertrophic type of actinic keratosis.
  • BACKGROUND: Recent investigations consider actinic keratosis (AK) as an earliest visible pattern of squamous cell carcinoma (SCC).
  • We have analysed the expression of apoptosis-related proteins TP53, Bcl-2 and Bax in 30 atrophic and 30 hypertrophic AK cases.
  • RESULTS: Expression of TP53 showed no significant differences between two analysed groups (chi2-test, P = 0.35636) whereas expression of Bcl-2 and Bax protein was significantly higher in atrophic compared to hypertrophic AK (chi2-test, P = 0.01458 and P = 0.00358, respectively).
  • Comparison of Bcl-2 : Bax ratio in two analysed AK showed significantly higher value in hypertrophic compared to atrophic AK (Mann-Whitney U test, P = 0.02272).
  • CONCLUSIONS: Our results may indicate higher resistance of keratinocytes on apoptotic stimuli in hypertrophic compared to atrophic AK.
  • Thus, we suppose that keratinocytes in hypertrophic AK live longer and probably have higher propensity for additional mutations and conversion to overt SCC.
  • [MeSH-major] Keratosis / metabolism. bcl-2-Associated X Protein / metabolism. bcl-X Protein / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16405608.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein; 0 / bcl-X Protein
  •  go-up   go-down


30. Piaserico S, Belloni Fortina A, Rigotti P, Rossi B, Baldan N, Alaibac M, Marchini F: Topical photodynamic therapy of actinic keratosis in renal transplant recipients. Transplant Proc; 2007 Jul-Aug;39(6):1847-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical photodynamic therapy of actinic keratosis in renal transplant recipients.
  • Organ transplant recipients (OTRs) show an increased risk of precancerous (mostly actinic keratosis [AK]) and cancerous (mostly squamous cell carcinomas [SCC] and basal cell carcinomas [BCC]) cutaneous lesions.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Keratosis / drug therapy. Kidney Transplantation / adverse effects. Photochemotherapy. Photosensitivity Disorders / drug therapy. Photosensitizing Agents / therapeutic use. Postoperative Complications / drug therapy

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17692630.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / delta-aminolevulinic acid methyl ester; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


31. Zaravinos A, Kanellou P, Spandidos DA: Viral DNA detection and RAS mutations in actinic keratosis and nonmelanoma skin cancers. Br J Dermatol; 2010 Feb 1;162(2):325-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Viral DNA detection and RAS mutations in actinic keratosis and nonmelanoma skin cancers.
  • BACKGROUND: Actinic keratosis (AK) is a well-established precancerous skin lesion that has the potential to progress to squamous cell carcinoma (SCC).
  • METHODS: HPV, CMV, HSV and EBV detection was performed using polymerase chain reaction (PCR) in skin biopsies (26 AK, 12 SCC and 15 BCC samples) that were collected from immunocompetent patients.
  • The HPV incidence was eight of 26 (31%) in AK and eight of 53 (15%) in normal skin tissue.
  • The CMV incidence was two of 26 (8%) in AK and four of 12 (33%) in SCC.
  • Only three samples, one AK (4%), one BCC (6%) and one SCC (8%), were found to carry a G>T transversion at the second position of HRAS codon 12.
  • CONCLUSIONS: HPV DNA is detected in NMSC, AK and normal skin biopsies.
  • Moreover, we suggest that the HRAS codon 12 mutation is not a very common event in AK or NMSC.
  • [MeSH-major] Carcinoma, Basal Cell / virology. Carcinoma, Squamous Cell / virology. DNA, Viral / isolation & purification. Genes, ras / genetics. Keratosis, Actinic / virology. Skin Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19849697.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


32. Lee AD, Jorizzo JL: Optimizing management of actinic keratosis and photodamaged skin: utilizing a stepwise approach. Cutis; 2009 Sep;84(3):169-75
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimizing management of actinic keratosis and photodamaged skin: utilizing a stepwise approach.
  • The incidence of photodamaged skin and skin lesions of all degrees of severity, from actinic keratosis (AK) to skin cancers, has dramatically increased.
  • Actinic keratoses are pathologic, reflecting damage of essential skin cell functions and potentially progressing to invasive squamous cell carcinoma (SCC).
  • We propose a comprehensive 5-step approach for managing AK lesions and photodamaged skin that includes periodic clinical skin examinations; treating AK lesions with a combination of field- and lesion-directed therapy; and patient education regarding sun-protective measures and regular skin self-examinations.
  • [MeSH-major] Carcinoma, Squamous Cell / prevention & control. Keratosis, Actinic / therapy. Skin Aging / pathology. Skin Neoplasms / prevention & control
  • [MeSH-minor] Disease Progression. Humans. Patient Education as Topic. Risk Factors. Severity of Illness Index. Sunlight / adverse effects


33. Esmann S, Jemec GB: Management of actinic keratosis patients: a qualitative study. J Dermatolog Treat; 2007;18(1):53-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of actinic keratosis patients: a qualitative study.
  • OBJECTIVES: In order to reinforce the appropriate UV-related behaviour of patients with actinic keratosis (AK), it is of importance to understand the underlying psychological aspects of having AK.
  • MATERIALS AND METHODS: Open and systematic explorative interviews were conducted with 15 AK patients.
  • Partly based on topics found by the single interviews, two qualitative group interviews (n = 7) with AK patients were performed.
  • RESULTS: Important topics for patients with AK were found to relate to the way to act in the sun (leisure time and outdoor work), a changed appearance, the seriousness of the AK diagnosis, control of the disease, and the sense of illness due to AK.
  • Awareness of these topics is therefore recommended in the management of patient information related to AK.
  • [MeSH-major] Keratosis / psychology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17365267.001).
  • [ISSN] 0954-6634
  • [Journal-full-title] The Journal of dermatological treatment
  • [ISO-abbreviation] J Dermatolog Treat
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Sunscreening Agents
  •  go-up   go-down


34. Vasiljevic N, Hazard K, Dillner J, Forslund O: Four novel human betapapillomaviruses of species 2 preferentially found in actinic keratosis. J Gen Virol; 2008 Oct;89(Pt 10):2467-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four novel human betapapillomaviruses of species 2 preferentially found in actinic keratosis.
  • This study determined the complete genomes of four betapapillomaviruses of species 2 from skin lesions designated HPV-107, -110 and -111 and FA75[KI88-03], an isolate of an unpublished HPV type, and analysed their prevalence and viral loads in biopsies from SCC, actinic keratosis (AK), basal cell carcinoma, seborrhoeic keratosis and the healthy skin of 263 immunocompetent patients by HPV type-specific real-time PCR assays.
  • Overall, the four viruses were more common in AK than in healthy skin (odds ratio 5.0, 95 % confidence interval 1.4-17.5), but the prevalence and viral loads were low.
  • [MeSH-major] Betapapillomavirus / classification. Betapapillomavirus / isolation & purification. Keratosis / virology. Papillomavirus Infections / epidemiology
  • [MeSH-minor] Aged. Carcinoma, Basal Cell / epidemiology. Carcinoma, Basal Cell / virology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / virology. Female. Humans. Keratosis, Seborrheic / epidemiology. Keratosis, Seborrheic / virology. Male. Molecular Sequence Data. Phylogeny. Polymerase Chain Reaction / methods. Prevalence. Sequence Analysis, DNA. Skin / virology. Skin Neoplasms / epidemiology. Skin Neoplasms / virology. Species Specificity. Viral Load

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18796715.001).
  • [ISSN] 0022-1317
  • [Journal-full-title] The Journal of general virology
  • [ISO-abbreviation] J. Gen. Virol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ EF422221/ EU410347/ EU410348/ EU410349
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


35. Kleinpenning MM, Wolberink EW, Smits T, Blokx WA, van De Kerkhof PC, van Erp PE, Gerritsen RM: Fluorescence diagnosis in actinic keratosis and squamous cell carcinoma. Photodermatol Photoimmunol Photomed; 2010 Dec;26(6):297-302
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescence diagnosis in actinic keratosis and squamous cell carcinoma.
  • BACKGROUND: As different tissue types have distinct capabilities to accumulate protoporphyrin IX, fluorescence diagnosis with aminolevulinic acid-induced porphyrins (FDAP) could be used to discriminate between different types of tissue.
  • Previous results demonstrated higher fluorescence ratios in squamous cell carcinoma (SCC) compared with actinic keratoses (AKs).
  • METHODS: After 1 week of keratolytic pretreatment, FDAP was performed in 13 patients with 36 lesions suspected for AK or SCC.
  • Biopsies were taken for histopathological diagnosis and measurement of stratum corneum thickness.
  • RESULTS: No significant differences were found in the fluorescence ratio (lesional : non-lesional skin) between AKs and SCCs, although macroscopic fluorescence was significantly higher in Bowen's disease and micro-invasive SCCs.
  • The amount of hyperkeratosis, invasiveness and degree of differentiation seem to be responsible for variations in fluorescence intensity.
  • [MeSH-major] Aminolevulinic Acid / administration & dosage. Carcinoma, Squamous Cell / diagnosis. Fluorescence. Keratosis, Actinic / diagnosis. Photosensitizing Agents / administration & dosage. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Porphyrins / metabolism. Time Factors

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 John Wiley & Sons A/S.
  • (PMID = 21091787.001).
  • [ISSN] 1600-0781
  • [Journal-full-title] Photodermatology, photoimmunology & photomedicine
  • [ISO-abbreviation] Photodermatol Photoimmunol Photomed
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


36. Hensen P, Müller ML, Haschemi R, Ständer H, Luger TA, Sunderkötter C, Schiller M: Predisposing factors of actinic keratosis in a North-West German population. Eur J Dermatol; 2009 Jul-Aug;19(4):345-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predisposing factors of actinic keratosis in a North-West German population.
  • The growing incident rates of skin cancer and their corresponding precursor lesions, e.g. actinic keratosis (AK), among Caucasians have become an important public health problem.
  • A multicenter case-control study was conducted to identify the risk factors of AK of a prototypical Central European population.
  • Using multivariate analysis we identified ten independent variables predicting the AK risk.
  • Additionally, sun exposure for recreational reasons, denial of the use of sunscreens, painful sunburn episodes before the age of 20, and a familial history of skin malignancies are also significant independent correlates of AK.
  • Our epidemiological data suggest that constitutional susceptibility and sunlight exposure are equally involved in the onset of AK.
  • These measures should be able to reduce the excessive incidence rates of AK among Caucasians in Central Europe.
  • [MeSH-major] Keratosis, Actinic / etiology. Precancerous Conditions / etiology
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Chi-Square Distribution. Disease Susceptibility. Female. Germany / epidemiology. Humans. Logistic Models. Male. Middle Aged. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19470418.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] France
  •  go-up   go-down


37. Saglam O, Salama M, Meier F, Chaffins M, Ma C, Ormsby A, Lee M: Immunohistochemical staining of palisading basal cells in Bowen's disease and basal involvement in actinic keratosis: contrasting staining patterns suggest different cells of origin. Am J Dermatopathol; 2008 Apr;30(2):123-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical staining of palisading basal cells in Bowen's disease and basal involvement in actinic keratosis: contrasting staining patterns suggest different cells of origin.
  • Actinic keratosis (AK) and Bowen's disease (BD) are common patterns of in situ squamous cell carcinoma of the epidermis.
  • In AK, atypical keratinocytes proliferate in the lower portion of the epidermis including the basal layer.
  • To characterize immunohistochemically keratocyte proliferation in AK and Palisading Basal Cells (PBC) in BD, we stained microarray samples of 45 AK and 25 BD with Molecular Immunology Borstel (MIB-1).
  • Subsequent immunostaining of full mounted sections examined 11 BD, 7 AK, and 4 examples of psoriasis for MIB-1 (as a proliferative marker) and p53 (as a cell cycle regulatory marker).
  • AK stained for MIB-1 and p53 antibodies only in lower portion of epidermis and included the basal layer.
  • Normal epidermis adjacent to the lesions in AK and BD biopsies stained sparsely in the basal layers.
  • The correlation of different histologic patterns of epidermal involvement with different immunohistochemical patterns of stains argues for different cells of origin for BD versus AK.
  • Conversely in AK, expression of MIB-1 and p53 in basal cells argues that these cells play a role in histogenesis of AK.
  • [MeSH-major] Bowen's Disease / pathology. Carcinoma, Basal Cell / pathology. Keratosis / pathology. Ki-67 Antigen / metabolism. Skin Neoplasms / pathology. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Biopsy, Needle. Cohort Studies. Diagnosis, Differential. Female. Gene Expression Regulation, Neoplastic. Humans. Immunoenzyme Techniques. Immunohistochemistry. Male. Middle Aged. Sensitivity and Specificity. Staining and Labeling / methods

  • Genetic Alliance. consumer health - Bowen's Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18360114.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


38. Talghini S, Halimi M, Baybordi H: Expression of P27, Ki67 and P53 in squamous cell carcinoma, actinic keratosis and Bowen disease. Pak J Biol Sci; 2009 Jun 15;12(12):929-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of P27, Ki67 and P53 in squamous cell carcinoma, actinic keratosis and Bowen disease.
  • This study aims at evaluating the expression of P27, Ki67 and P53 in Squamous Cell Carcinoma (SCC), Actinic Keratosis (AK) and Bowen Disease (BD) specimens.
  • In an analytic-descriptive setting, skin biopsy specimens of 45 patients were evaluated in three 15-case groups including BD, AK and SCC specimens.
  • Ki67 was expressed in 0.8, 23.7, 12.3 and 19.3% of the cells in the normal skin, AK, BD and SCC groups, respectively.
  • P27 was positive in 23.4, 26.2, 25.9 and 4.5% of specimens in the normal skin, AK, BD and SCC groups, respectively.
  • P53 expression was detected in 26.6, 41.8 and 54.6% of the assessed cells in the AK, BD and SCC groups, respectively.
  • Based on these results, the quantitative and qualitative (pattern of distribution) evaluation of the expressions of Ki67, P27 and P53 may be helpful in differentiating malignant and premalignant epidermal lesions, particularly in unsatisfactory or fragmented specimens.
  • [MeSH-major] Bowen's Disease / metabolism. Carcinoma, Squamous Cell / metabolism. Intracellular Signaling Peptides and Proteins / metabolism. Keratosis, Actinic / metabolism. Ki-67 Antigen / metabolism. Skin Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Cyclin-Dependent Kinase Inhibitor p27. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Skin / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19777788.001).
  • [ISSN] 1028-8880
  • [Journal-full-title] Pakistan journal of biological sciences : PJBS
  • [ISO-abbreviation] Pak. J. Biol. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / CDKN1B protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / Ki-67 Antigen; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


39. Dissemond J, Grabbe S: [Actinic keratosis]. MMW Fortschr Med; 2006 Jun 15;148(24):38-9, 41
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Actinic keratosis].
  • [Transliterated title] Krebsvorstufe aktinische Keratose. So erkennen Sie gefährliche Sonnenschäden.
  • Actinic keratosis is a precancerous lesion that is commonly seen in the elderly patient and requires treatment.
  • The diagnosis is usually based on the clinical appearance of the lesion.
  • [MeSH-major] Carcinoma, Squamous Cell / etiology. Keratosis. Precancerous Conditions. Skin Neoplasms / etiology. Ultraviolet Rays / adverse effects
  • [MeSH-minor] Adjuvants, Immunologic / administration & dosage. Adjuvants, Immunologic / therapeutic use. Age Factors. Aged. Aminoquinolines / administration & dosage. Aminoquinolines / therapeutic use. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Cryotherapy. Diagnosis, Differential. Female. Fluorouracil / administration & dosage. Fluorouracil / therapeutic use. Humans. Interferon Inducers / administration & dosage. Interferon Inducers / therapeutic use. Laser Therapy. Male. Ointments. Photochemotherapy. Risk Factors. Time Factors

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16850807.001).
  • [ISSN] 1438-3276
  • [Journal-full-title] MMW Fortschritte der Medizin
  • [ISO-abbreviation] MMW Fortschr Med
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Interferon Inducers; 0 / Ointments; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil
  • [Number-of-references] 0
  •  go-up   go-down


40. Colombo GL, Chimenti S, Di Matteo S, Fargnoli MC, Frascione P, Silipo V, Peris K: Cost-effectiveness analysis of topical treatments for actinic keratosis in the perspective of the Italian health care system. G Ital Dermatol Venereol; 2010 Oct;145(5):573-81
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-effectiveness analysis of topical treatments for actinic keratosis in the perspective of the Italian health care system.
  • Actinic keratosis (AK) is the most common cutaneous malignant neoplasm and its prevalence continues to increase.
  • According to the most recent findings, AK is currently considered the initial stage, in situ, of squamous cell carcinoma.
  • Based on this cost-effectiveness model, diclofenac 3% in HA can be considered the treatment of choice for AK lesions and surrounding field under a pharmacoeconomic point of view.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Aminoquinolines / economics. Aminoquinolines / therapeutic use. Diclofenac / economics. Diclofenac / therapeutic use. Keratosis, Actinic / drug therapy. Keratosis, Actinic / economics

  • Hazardous Substances Data Bank. DICLOFENAC .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20930692.001).
  • [ISSN] 0392-0488
  • [Journal-full-title] Giornale italiano di dermatologia e venereologia : organo ufficiale, Società italiana di dermatologia e sifilografia
  • [ISO-abbreviation] G Ital Dermatol Venereol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / methyl 5-aminolevulinate; 144O8QL0L1 / Diclofenac; 88755TAZ87 / Aminolevulinic Acid; 99011-02-6 / imiquimod
  •  go-up   go-down


41. Halpern AC, Kopp LJ: Awareness, knowledge and attitudes to non-melanoma skin cancer and actinic keratosis among the general public. Int J Dermatol; 2005 Feb;44(2):107-11
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Awareness, knowledge and attitudes to non-melanoma skin cancer and actinic keratosis among the general public.
  • In a structured telephone interview lasting approximately 10 min, respondents answered questions on NMSC, specifically actinic keratosis (AK) and basal cell carcinoma (BCC).
  • Countries with a high incidence of NSMC had greater awareness of the condition, with more awareness of BCC than AK.
  • [MeSH-major] Carcinoma, Basal Cell. Health Knowledge, Attitudes, Practice. Keratosis. Photosensitivity Disorders. Skin Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15689206.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. da Silva TA, Coelho G, Lorenzetti Bocca A, Figueiredo Cavalcante Neto F: Expression of apoptotic, cell proliferation regulatory, and structural proteins in actinic keratosis and their association with dermal elastosis. J Cutan Pathol; 2007 Apr;34(4):315-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of apoptotic, cell proliferation regulatory, and structural proteins in actinic keratosis and their association with dermal elastosis.
  • BACKGROUND: Actinic keratosis (AK) is a premalignant lesion caused by ultraviolet (UV) radiation and characterized by epithelial and connective tissue alterations.
  • However, little is known about the link between connective and UV-damaged epithelial tissues in AK.
  • OBJECTIVE AND METHODS: To examine the potential relationship between connective tissue degeneration and molecular alterations in epithelial cells without evident morphologic changes, 30 cases of AK (8, grade I; 10, grade II; 12, grade III), divided into three grades according to the proportion of dermal elastosis (in grade I, up to 30% of collagen degeneration; in grade II, 30-60%; in grade III, more than 60%), were immunohistochemically analyzed for the expression of Ki67, p53, p63, bcl-2, E-cadherin, 34-betaE12, and CD99.
  • RESULTS: The increase in the solar elastosis grade was associated with an increase in positive cell numbers for all analyzed markers.
  • CONCLUSIONS: These results demonstrate that the epithelial expression of apoptotic, cell proliferation, and structural proteins is augmented with the increase of the solar elastosis grade.
  • Thus, the grade of solar elastosis could be a helpful morphologic marker in the assessment of neoplastic changes in sun-damaged skin.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17381802.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


43. Röwert-Huber J, Patel MJ, Forschner T, Ulrich C, Eberle J, Kerl H, Sterry W, Stockfleth E: Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol; 2007 May;156 Suppl 3:8-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification.
  • The term actinic keratosis (AK) describes a sun-induced, clinical erythematous lesion covered with scale, but does not provide an understanding of the biology or histopathology of the lesion.
  • Consequently, several classification systems for AK have been suggested, but as yet no consensus has been reached.
  • AK is a clinical description that has a histological diagnosis consistent with squamous cell carcinoma (SCC) in situ.
  • We recommend an AK classification system that describes these lesions as squamous cell carcinomas (SCCs), using the terminology 'early in situ SCC Type AK I', 'early in situ SCC type AK II' and 'in situ SCC Type AK III', there by giving clinicians better guidance for diagnosis and specific treatment recommendations.
  • [MeSH-major] Carcinoma in Situ / classification. Carcinoma, Squamous Cell / classification. Keratosis / classification. Skin Neoplasms / classification

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Br J Dermatol. 2007 Aug;157(2):431
  • (PMID = 17488400.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


44. Dang C, Gottschling M, Roewert J, Forschner T, Stockfleth E, Nindl I: Tenascin-C patterns and splice variants in actinic keratosis and cutaneous squamous cell carcinoma. Br J Dermatol; 2006 Oct;155(4):763-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tenascin-C patterns and splice variants in actinic keratosis and cutaneous squamous cell carcinoma.
  • The mRNA expression and protein level of Tn-C including its various isoforms have not been investigated comprehensively so far in cutaneous squamous cell carcinoma (SCC) and the precursor lesion actinic keratosis (AK).
  • METHODS: Biopsies from 66 patients (or representative subsets) that comprised 25 specimens from normal skin, 19 AK and 22 cutaneous SCC were analysed for Tn-C splice variants using splice-specific primers.
  • RESULTS: The large Tn-C splice variant was present in only 5% of normal skin samples, in comparison with 63% of AK (P < 0.001) and 88% of SCC (P < 0.001).
  • Tn-C mRNA expression was significantly increased in AK and SCC compared with normal skin (P < 0.001).
  • The corresponding proteins were rarely detected in cells of the vascular epithelial layers and perifollicular layers of some normal skin specimens, and their spatial localization expanded into the papillary dermis of AK.
  • CONCLUSIONS: Tn-C is present in the dermis, its expression is increased during skin cancer development, and the large splice variant is characteristic for AK and SCC, which may prove useful for diagnostic approaches in cutaneous SCC.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Keratosis / metabolism. Precancerous Conditions / metabolism. Skin Neoplasms / metabolism. Tenascin / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965426.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / Tenascin
  •  go-up   go-down


45. Puizina-Ivić N, Sapunar D, Marasović D, Mirić L: An overview of Bcl-2 expression in histopathological variants of basal cell carcinoma, squamous cell carcinoma, actinic keratosis and seborrheic keratosis. Coll Antropol; 2008 Oct;32 Suppl 2:61-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An overview of Bcl-2 expression in histopathological variants of basal cell carcinoma, squamous cell carcinoma, actinic keratosis and seborrheic keratosis.
  • In this study the authors have analyzed imunohistochemically the expression of Bcl-2 protein in the histopathological variants of the most common malignant tumors of the skin--basal cell carcinoma (BCC) and squamous cell tumor (SCC), as well as in the precancerous lesion actinic keratosis (AK) and in benign tumor seborrheic keratosis (SK).
  • In cases of hypertrophic and atrophic variants of AK, Bcl-2 expression was confined to basal cell layer, as well as in one case of hypertrophic variant in suprabasal cells.
  • In three histological variants of SK expresseion of Bcl-2 protein was in areas of basaloid proliferation, while in areas of squamous differentiation was negative.
  • In AK results suggest that immunoreactivity is regulated with respect of the keratinocyte's differentiation status, but not closely correlate with proliferative rate.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Keratosis, Actinic / metabolism. Keratosis, Seborrheic / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Skin Neoplasms / metabolism


46. Shin JW, Kim YK, Cho KH: Minichromosome maintenance protein expression according to the grade of atypism in actinic keratosis. Am J Dermatopathol; 2010 Dec;32(8):794-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minichromosome maintenance protein expression according to the grade of atypism in actinic keratosis.
  • The aim of this study was to characterize the pattern and frequency of MCM 2 protein expression in actinic keratosis (AK) and determine whether the expression is correlated with the degree of histological atypism.
  • Biopsy samples of 34 patients who had been diagnosed as AK were used in this study.
  • MCM 2 protein was expressed in atypical keratinocytes in AK.
  • Moreover, the correlation between the immunoreactivity for MCM 2 protein and AK grade was significantly more positive than that for other markers.
  • Thus, we suggest that MCM 2 protein is a reliable marker for diagnosing and grading AK and further could be hypothesized as an important prognostic factor.
  • [MeSH-major] Cell Cycle Proteins / analysis. Keratinocytes / chemistry. Keratosis, Actinic / metabolism. Nuclear Proteins / analysis. Skin / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20847638.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cell Cycle Proteins; 0 / Ki-67 Antigen; 0 / Nuclear Proteins; 0 / Proliferating Cell Nuclear Antigen; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  •  go-up   go-down


47. Nindl I, Gottschling M, Krawtchenko N, Lehmann MD, Röwert-Huber J, Eberle J, Stockfleth E, Forschner T: Low prevalence of p53, p16(INK4a) and Ha-ras tumour-specific mutations in low-graded actinic keratosis. Br J Dermatol; 2007 May;156 Suppl 3:34-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low prevalence of p53, p16(INK4a) and Ha-ras tumour-specific mutations in low-graded actinic keratosis.
  • Different mutation rates of p53, p16(INK4a) and Ha-ras in cutaneous squamous cell carcinoma (SCC) and the earlier stage actinic keratosis (AK) have been reported.
  • OBJECTIVES: To assess the presence of missense mutations in hotspot exons of p53, p16(INK4a) and Ha-ras in low-graded AK.
  • PATIENTS/METHODS: Cryo-biopsies of 75 sun-exposed AK lesions and 75 sun-shielded areas of normal skin from 75 AK patients were analysed to identify mutations in p53 (exons 7 and 8), p16(INK4a) (exon 2) and Ha-ras (exon 1) using polymerase chain reaction (PCR) followed by direct sequencing.
  • As a representative subset of the specimens, ten mutation-negative AK were also micro-dissected in order to exclude the possibility that additional mutations were undetected.
  • RESULTS: Eight missense and one nonsense point mutations were found in the 75 AK lesions examined (12%), of which seven (9%) were tumour-specific (i.e. present in AK lesions only) and two (3%) were p16(INK4a) mutations (i.e. also detected in normal skin).
  • CONCLUSIONS: The evaluation of a large number of AK specimens in this study have found a low gene mutation rate in low-graded AK lesions. p53 mutations rather than p16(INK4a) and/or Ha-ras mutations may be an early event in the development of AK to cutaneous SCC.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Genes, p53 / genetics. Genes, ras / genetics. Keratosis / genetics. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488404.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16
  •  go-up   go-down


48. Neidecker MV, Davis-Ajami ML, Balkrishnan R, Feldman SR: Pharmacoeconomic considerations in treating actinic keratosis. Pharmacoeconomics; 2009;27(6):451-64
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacoeconomic considerations in treating actinic keratosis.
  • Actinic keratosis is among the most commonly treated skin conditions in the outpatient setting.
  • The purpose of this article is to review published economic studies relating to the treatment of actinic keratosis, to summarize results discussing the cost drivers of current treatment modalities and to identify parameters most likely to influence the cost effectiveness of treatment.
  • We systematically conducted a published literature search for pharmacoeconomic research of actinic keratosis using title, abstract or full-text searches with the following search terms ([actinic OR solar] AND [keratosis OR keratoses]) AND (economic OR cost OR pharmacoeconomics OR decision).
  • We included published articles referencing actinic keratosis in a standalone study or in a broader study referencing non-melanoma skin cancer and articles evaluating cost-of-illness, cost-of-treatment, cost minimization, cost effectiveness, cost utility, cost-benefit analysis and cost consequence.
  • Our review of the literature found nine studies devoted to pharmacoeconomic considerations of actinic keratosis treatments, with one article investigating both cost-of-illness and cost-of-treatment, two measuring cost-of-illness, two evaluating cost-of-treatment, one focusing on cost minimization, and three focusing on cost effectiveness.
  • The literature compared a broad range of actinic keratosis treatments including topical medications, cryotherapy, photodynamic therapy, excision and a combination of treatment modalities.
  • The direct cost of actinic keratosis management in the US was estimated at $US1.2 billion per year, with indirect costs totalling $US295 million (year 2004 values).
  • Pharmacoeconomic research defining standards, outcomes and areas of efficiencies in the treatment of actinic keratosis is in its infancy.
  • [MeSH-major] Cost of Illness. Economics, Pharmaceutical / statistics & numerical data. Keratosis, Actinic / economics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dermatol Surg. 2005 Jan;31(1):43-7 [15720095.001]
  • [Cites] Eur J Dermatol. 2006 Nov-Dec;16(6):599-606 [17229598.001]
  • [Cites] J Am Acad Dermatol. 2008 May;58(5 Suppl 2):S149-54 [18410801.001]
  • [Cites] J Am Acad Dermatol. 2000 Jan;42(1 Pt 2):8-10 [10607350.001]
  • [Cites] Pharmacoeconomics. 2004;22(2):83-94 [14731050.001]
  • [Cites] Eur J Dermatol. 2008 Sep-Oct;18(5):539-46 [18693157.001]
  • [Cites] Br J Dermatol. 2007 May;156 Suppl 3:40-2 [17488405.001]
  • [Cites] J Surg Oncol. 2001 Jun;77(2):76-8 [11398156.001]
  • [Cites] J Drugs Dermatol. 2008 Jan;7(1):23-5 [18246694.001]
  • [Cites] Arch Dermatol. 1991 Jul;127(7):1029-31 [2064402.001]
  • [Cites] J Am Acad Dermatol. 2008 May;58(5):769-80 [18328594.001]
  • [Cites] Cutis. 2002 Aug;70(2 Suppl):30-6 [12353678.001]
  • [Cites] J Am Acad Dermatol. 2000 Jan;42(1 Pt 2):25-8 [10607354.001]
  • [Cites] Dermatol Surg. 2006 Aug;32(8):1045-9 [16918567.001]
  • [Cites] Med J Aust. 1983 Dec 10-24;2(12):619-22 [6669125.001]
  • [Cites] Br J Dermatol. 2002 Apr;146 Suppl 61:1-6 [11966724.001]
  • [Cites] Am J Epidemiol. 2007 Mar 15;165(6):719-26 [17204514.001]
  • [Cites] Epithelial Cell Biol. 1992 Jan;1(1):47-51 [1307938.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1681-91 [12711744.001]
  • [Cites] Br J Dermatol. 2007 Feb;156(2):222-30 [17223860.001]
  • [Cites] J Dermatolog Treat. 2009;20(5):266-75 [19421918.001]
  • [Cites] Lancet. 1988 Apr 9;1(8589):795-7 [2895318.001]
  • [Cites] Br J Dermatol. 2006 Oct;155(4):784-90 [16965429.001]
  • [Cites] Health Aff (Millwood). 2004 Jan-Jun;Suppl Web Exclusives:W4-297-9 [15451996.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2196-8 [15152066.001]
  • [Cites] J Am Acad Dermatol. 1988 Dec;19(6):1045-52 [3204179.001]
  • [Cites] Dermatol Clin. 2006 Apr;24(2):271-80, viii [16677973.001]
  • [Cites] Br J Dermatol. 1994 Oct;131(4):455-64 [7947197.001]
  • [Cites] Int J Dermatol. 2006 Mar;45(3):272-6 [16533227.001]
  • [Cites] Pharmacoeconomics. 2004;22(18):1195-208 [15606226.001]
  • [Cites] Br J Dermatol. 2007 Jun;156(6):1393-4 [17535242.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):125-43 [17190630.001]
  • [Cites] J Am Acad Dermatol. 2003 Mar;48(3):425-9 [12637924.001]
  • [Cites] Dermatol Ther. 2007 Sep-Oct;20(5):360-76 [18045361.001]
  • [Cites] J Invest Dermatol. 2000 Aug;115(2):273-7 [10951246.001]
  • [Cites] BMJ. 1996 Aug 3;313(7052):275-83 [8704542.001]
  • [Cites] Int J Dermatol. 2004 Sep;43(9):638-42 [15357741.001]
  • [Cites] J Am Acad Dermatol. 1999 Jul;41(1):81-99 [10411417.001]
  • [Cites] Ann Intern Med. 2008 Jun 17;148(12):956-61 [18483128.001]
  • [Cites] Am Fam Physician. 2007 Sep 1;76(5):667-71 [17894135.001]
  • [Cites] Br J Dermatol. 2003 Nov;149 Suppl 66:40-2 [14616348.001]
  • (PMID = 19640009.001).
  • [ISSN] 1170-7690
  • [Journal-full-title] PharmacoEconomics
  • [ISO-abbreviation] Pharmacoeconomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] New Zealand
  • [Number-of-references] 48
  •  go-up   go-down


49. Del Rosso JQ: The use of topical imiquimod for the treatment of actinic keratosis: a status report. Cutis; 2005 Oct;76(4):241-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of topical imiquimod for the treatment of actinic keratosis: a status report.
  • Topical imiquimod 5% cream is approved for the treatment of actinic keratosis (AK), superficial basal cell carcinoma, and external genital warts.
  • This article reviews available data on the use of topical imiquimod for AK.
  • Topical imiquimod is an effective and safe treatment option for AK that produces complete eradication or marked reduction in the number of lesions in most patients.
  • Recent evidence suggests that many patients who effectively are cleared of AK lesions after topical imiquimod use remain free of lesions for several months to 2 years or develop a minimal number of new AK lesions.
  • [MeSH-major] Aminoquinolines / therapeutic use. Keratosis / drug therapy

  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315560.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 99011-02-6 / imiquimod
  • [Number-of-references] 39
  •  go-up   go-down


50. Mogensen M, Nürnberg BM, Forman JL, Thomsen JB, Thrane L, Jemec GB: In vivo thickness measurement of basal cell carcinoma and actinic keratosis with optical coherence tomography and 20-MHz ultrasound. Br J Dermatol; 2009 May;160(5):1026-33
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo thickness measurement of basal cell carcinoma and actinic keratosis with optical coherence tomography and 20-MHz ultrasound.
  • METHODS: In total, 93 patients were scanned and 34 lesions [23 basal cell carcinoma (BCC) and 11 actinic keratosis (AK) lesions] < 2 mm thick and easily identified in OCT images were studied.
  • CONCLUSIONS: OCT appears more precise and less biased than HFUS for thickness measurement in AK and BCC lesions < 2 mm, but both OCT and especially HFUS tended to overestimate tumour thickness.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Keratosis, Actinic / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Dermatol. 2014 Mar;170(3):737-9 [24124649.001]
  • (PMID = 19183171.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


51. Giuffrè G, Barresi V, Catalano A, Cappiello A, Stagno d'Alcontres F, Tuccari G: Actinic keratosis associated with squamous and basal cell carcinomas: an evaluation of neoplastic progression by a standardized AgNOR analysis. Eur J Histochem; 2008 Jan-Mar;52(1):53-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Actinic keratosis associated with squamous and basal cell carcinomas: an evaluation of neoplastic progression by a standardized AgNOR analysis.
  • In an attempt to investigate the neoplastic progression in different stages of actinic keratosis (AK), a standardized AgNOR analysis was performed in 94 cases of AK, 35 of which were associated with squamous cell carcinoma (SCC) or basal cell carcinoma (BCC), and in 31 cases of SCC and 22 cases of BCC.
  • The cases were subdivided into low- and high-AgNOR-expressing (AgNOR status) AK by using the mean area of AgNORs per cell (NORA) value (3.996 micro(2)) as the cut-off.
  • In AK samples, a progressive increase of the mean NORA value from Stage I to Stage IV was encountered.
  • In addition, a significantly higher mean NORA value was found in the AK cases associated with SCC, in comparison to those without SCC; by contrast, no significant differences in the mean NORA value were noted between AK cases with or without BCC.
  • A highly significant association between a high AgNOR quantity and the coexistence of SCC was encountered in AK; no association was appreciable between the AgNOR quantity and the co-occurrence of BCC.
  • Moreover, when the co-existence of SCC in AK was considered as the reference point, the AK cases associated with SCC mostly (95.5%) presented a high AgNOR quantity (high sensitivity), but only 57.6% of cases without SCC displayed a low AgNOR quantity (low specificity).
  • Additionally, our data document that the standardised AgNOR analysis represents a strong negative predictor for the association between SCC and AK.
  • Indeed, a low AgNOR quantity mostly is associated with AK cases without SCC.
  • [MeSH-major] Antigens, Nuclear / analysis. Carcinoma, Basal Cell / chemistry. Carcinoma, Squamous Cell / chemistry. Keratosis / metabolism. Nucleolus Organizer Region / chemistry. Skin Neoplasms / chemistry
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Male. Middle Aged. Prognosis. Silver Staining

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18502723.001).
  • [ISSN] 1121-760X
  • [Journal-full-title] European journal of histochemistry : EJH
  • [ISO-abbreviation] Eur J Histochem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / nucleolar organizer region associated proteins
  •  go-up   go-down


52. Lee PK, Harwell WB, Loven KH, Phillips TJ, Whiting DA, Andres KL, Lee JH: Long-term clinical outcomes following treatment of actinic keratosis with imiquimod 5% cream. Dermatol Surg; 2005 Jun;31(6):659-64
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term clinical outcomes following treatment of actinic keratosis with imiquimod 5% cream.
  • BACKGROUND: The results from four phase III, randomized, vehicle-controlled studies showed that imiquimod 5% cream (imiquimod) was safe and effective in the treatment of actinic keratosis (AK).
  • Patients applied imiquimod or vehicle cream to AK lesions on the face or balding scalp, dosing three times per week or two times per week for 16 weeks.
  • OBJECTIVE: To obtain long-term safety follow-up data and estimate AK recurrence in patients who completely cleared their AK lesions in the treatment area at the 8-week post-treatment visit in the phase III studies.
  • METHODS: One hundred forty-six patients from 30 study centers in the United States were evaluated for clinical evidence of AK, and safety data were collected.
  • RESULTS: After a median follow-up period of 16 months, 24.7% (19 of 77) of the patients administered imiquimod three times per week and 42.6% (23 of 54) of the patients administered imiquimod two times per week had a recurrence of AK (the appearance of at least one AK lesion) in the original treatment area.
  • The median number of AK lesions present was one lesion for both patients receiving imiquimod three times and those receiving imiquimod two times per week compared with a median of six lesions at baseline in the combined three times per week and two times per week phase III studies.
  • CONCLUSION: One and a half years following treatment, imiquimod continued to provide a long-term clinical benefit in a majority of patients who experienced complete clearance of their AK lesions.
  • [MeSH-major] Adjuvants, Immunologic / administration & dosage. Aminoquinolines / administration & dosage. Keratosis / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15996416.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase IV; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 99011-02-6 / imiquimod
  •  go-up   go-down


53. Szeimies RM, Bichel J, Ortonne JP, Stockfleth E, Lee J, Meng TC: A phase II dose-ranging study of topical resiquimod to treat actinic keratosis. Br J Dermatol; 2008 Jul;159(1):205-10
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II dose-ranging study of topical resiquimod to treat actinic keratosis.
  • BACKGROUND: Resiquimod, a toll-like receptor 7 and 8 agonist, may be effective as a topical treatment of actinic keratosis (AK).
  • METHODS: Patients with AK lesions on the face or balding scalp were randomly assigned to resiquimod 0.01%, 0.03%, 0.06% or 0.1% gel applied once daily three times a week for 4 weeks to a contiguous 25-cm(2) area with four to eight lesions.
  • CONCLUSIONS: Efficacy in clearing AK lesions was similar between the resiquimod concentrations evaluated, but resiquimod 0.01% and 0.03% were better tolerated than the higher concentrations.
  • [MeSH-major] Imidazoles / therapeutic use. Keratosis / drug therapy. Precancerous Conditions / prevention & control. Skin Neoplasms / prevention & control. Toll-Like Receptor 7 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18476957.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gels; 0 / Imidazoles; 0 / TLR7 protein, human; 0 / Toll-Like Receptor 7; V3DMU7PVXF / resiquimod
  •  go-up   go-down


54. Torres A, Storey L, Anders M, Miller RL, Bulbulian BJ, Jin J, Raghavan S, Lee J, Slade HB, Birmachu W: Microarray analysis of aberrant gene expression in actinic keratosis: effect of the Toll-like receptor-7 agonist imiquimod. Br J Dermatol; 2007 Dec;157(6):1132-47
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microarray analysis of aberrant gene expression in actinic keratosis: effect of the Toll-like receptor-7 agonist imiquimod.
  • BACKGROUND: The molecular events leading to actinic keratosis (AK) are not well understood.
  • OBJECTIVE: To identify and compare gene expression changes in AK lesions and in sun-exposed nonlesional skin and to determine the effect of imiquimod 5% cream on these changes.
  • METHOD: A double-blind, vehicle-controlled, randomized study was conducted to evaluate the molecular changes in AK treated with imiquimod.
  • Seventeen male subjects with >/= 5 AK lesions on the scalp applied vehicle or imiquimod three times a week for 4 weeks.
  • RESULTS: We identified gene expression changes which occur in sun-exposed, nonlesional skin as well as in AK lesions.
  • The gene expression changes observed in AK lesions and in sun-exposed, nonlesional skin were consistent with the confocal microscopy observations, which showed abnormalities in the sun-exposed, nonlesional skin, similar in nature but less pronounced than abnormalities seen in AK.
  • Imiquimod partially or totally reversed the aberrant expression of some of the genes observed in AK, consistent with clearing of lesions and normalization of confocal cellular images.
  • CONCLUSIONS: The data show that profound gene expression changes occur in sun-exposed, nonlesional skin which progress further in AK lesions.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Gene Expression / drug effects. Keratosis / genetics. Photosensitivity Disorders / genetics. Scalp Dermatoses / genetics. Toll-Like Receptor 7 / agonists

  • MedlinePlus Health Information. consumer health - Dandruff, Cradle Cap, and Other Scalp Conditions.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17944981.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Toll-Like Receptor 7; 99011-02-6 / imiquimod
  •  go-up   go-down


55. Caekelbergh K, Annemans L, Lambert J, Roelandts R: Economic evaluation of methyl aminolaevulinate-based photodynamic therapy in the management of actinic keratosis and basal cell carcinoma. Br J Dermatol; 2006 Oct;155(4):784-90
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Economic evaluation of methyl aminolaevulinate-based photodynamic therapy in the management of actinic keratosis and basal cell carcinoma.
  • BACKGROUND: Various effective therapeutic options are currently available for the treatment of actinic keratosis (AK) and basal cell carcinoma (BCC), but none is perfect.
  • OBJECTIVES: To evaluate the cost-effectiveness of a recent approach, methyl aminolaevulinate-based photodynamic therapy (MAL-PDT; Metvix; Galderma, Lausanne, Switzerland) in AK and BCC.
  • The time horizon was 1 year for AK and 5 years for BCC.
  • The comparators were cryotherapy in AK and excision surgery in BCC.
  • RESULTS: MAL-PDT is a more expensive treatment compared with cryotherapy for AK.
  • CONCLUSIONS: The results suggest that MAL-PDT is a cost-effective intervention in AK taking a 1-year time horizon, if society is willing to pay euro1.50 per day of response, and that MAL-PDT is better value for money than excision in BCC, taking a 5-year time horizon.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Carcinoma, Basal Cell / economics. Keratosis / economics. Photochemotherapy / economics. Skin Neoplasms / economics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Dermatol. 2007 Jun;156(6):1393-4 [17535242.001]
  • [CommentIn] Br J Dermatol. 2007 Jun;156(6):1392; author reply 1393 [17535240.001]
  • (PMID = 16965429.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


56. Bagazgoitia L, Cuevas J, Juarranz A: Expression of p53 and p16 in actinic keratosis, bowenoid actinic keratosis and Bowen's disease. J Eur Acad Dermatol Venereol; 2010 Feb;24(2):228-30
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p53 and p16 in actinic keratosis, bowenoid actinic keratosis and Bowen's disease.
  • INTRODUCTION: Bowen's disease (BD) and bowenoid actinic keratosis (bAK) have traditionally been differentiated according to the presence or absence of dysplasia in the follicular epithelium. p16 has been suggested to be a useful tool to make the differential diagnosis between BD and AK and as a marker of bad prognosis.
  • MATERIALS: Five biopsies of BD, five of AK and five of bAK where stained for p53 and p16.
  • DISCUSSION AND CONCLUSION: These findings suggest a common pathogenic mechanism for BD and bAK. bAK might have worse prognosis than AK. p16 might not be useful as a tool for differential diagnosis between AK and BD because bAK and BD show an extremely similar immunohistochemical pattern.
  • [MeSH-major] Bowen's Disease / metabolism. Genes, p16. Keratosis, Actinic / metabolism. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Bowen's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19515076.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


57. Ortonne JP, Gupta G, Ortonne N, Duteil L, Queille C, Mallefet P: Effectiveness of cross polarized light and fluorescence diagnosis for detection of sub-clinical and clinical actinic keratosis during imiquimod treatment. Exp Dermatol; 2010 Jul 1;19(7):641-7
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of cross polarized light and fluorescence diagnosis for detection of sub-clinical and clinical actinic keratosis during imiquimod treatment.
  • BACKGROUND: During treatment of actinic keratosis (AK) lesions with imiquimod sub-clinical lesions often become visible.
  • OBJECTIVE: The aim of this pilot study was to compare two techniques, cross polarized light photography (CPL) and fluorescence diagnosis (FD) using methyllevulinic acid and illumination with Wood's lamp for their ability to detect sub-clinical lesions.
  • METHODOLOGY: Twelve patients with at least five clinically visible AK lesions in a single contiguous 20 cm(2) area on the head were recruited.
  • Patients were assessed for baseline AK lesion counts (clinical and sub-clinical) at the screening visit and final counts at week 20.
  • RESULTS: The number of clinically observed AK lesions was significantly lower at week 12 and week 20 compared with baseline following imiquimod treatment versus vehicle.
  • CONCLUSION: The number of sub-clinical and clinical AK lesions detected during treatment with imiquimod can be better demonstrated using the methods of CPL and FD, but statistical significance was reached only using the CPL method.
  • However, results were encouraging and indicate that larger studies are needed to demonstrate the relevance of these two new methods for improved detection of clinical and especially sub-clinical AK lesions.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Keratosis, Actinic / diagnosis. Keratosis, Actinic / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20201959.001).
  • [ISSN] 1600-0625
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Levulinic Acids; 0 / Photosensitizing Agents; 3Q95S830W6 / methyl levulinate; 99011-02-6 / imiquimod
  •  go-up   go-down


58. Kanellou P, Zaravinos A, Zioga M, Stratigos A, Baritaki S, Soufla G, Zoras O, Spandidos DA: Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis. Cancer Lett; 2008 Jun 8;264(1):145-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis.
  • Actinic keratosis (AK) is a well-established pre-cancerous skin lesion that has the potential to progress to squamous cell carcinoma (SCC).
  • We investigated the involvement of the CDKN2A, CDKN2B and p53 genes in AK and in the progression of AK to SCC.
  • Mutational analysis on exons 1a, 1b and 2 of the CDKN2A locus and exon 1 of the CDKN2B locus as well as allelic imbalance was performed in 26 AK specimens.
  • Two AK samples carried a not-previously described non-UV type missense mutation at codon 184 (Val184Glu) of exon 1b in the p14(ARF) gene.
  • Microsatellite instability (MSI) was found in 15% of AKs in at least one marker, indicating that genetic instability has some implication in the development of AK.
  • Down-regulation of p16(INK4a) and p53 mRNA levels was noted in SCC compared to AK.
  • Furthermore, we suggest a possible role of p15(INK4b), independently from the intracellular pathway mediated by p16(INK4a), and of p14(ARF) in AK development, as well as in the progression of AK to SCC.
  • The deregulation of the expression profiles of the CDKN2A, CDKN2B and p53 genes may, independently of mutations and LOH at 9p21, play a significant role in AK and progression of AK to SCC.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. Genomic Instability. Keratosis / genetics. Mutation. Precancerous Conditions / genetics. Tumor Suppressor Proteins / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18331779.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


59. Patel MJ, Stockfleth E: Does progression from actinic keratosis and Bowen's disease end with treatment: diclofenac 3% gel, an old drug in a new environment? Br J Dermatol; 2007 May;156 Suppl 3:53-6
Hazardous Substances Data Bank. DICLOFENAC .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does progression from actinic keratosis and Bowen's disease end with treatment: diclofenac 3% gel, an old drug in a new environment?
  • Progression from actinic keratosis (AK) and Bowen's disease (BD) to invasive disease involves a complex cascade of events.
  • The preparation of diclofenac 3% gel (Solaraze; Shire Pharmaceuticals) has been shown to be efficacious and well tolerated in AK.
  • Given its mechanism of action, we hypothosize that diclofenac 3% gel may have potential to halt the progression of actinic keratoses (AKs) in the setting of field cancerisation and BD.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Bowen's Disease / drug therapy. Diclofenac / administration & dosage. Keratosis / drug therapy
  • [MeSH-minor] Administration, Topical. Disease Progression. Gels. Humans. Treatment Outcome

  • Genetic Alliance. consumer health - Bowen's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488408.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Gels; 144O8QL0L1 / Diclofenac
  •  go-up   go-down


60. Moloney FJ, Collins P: Randomized, double-blind, prospective study to compare topical 5-aminolaevulinic acid methylester with topical 5-aminolaevulinic acid photodynamic therapy for extensive scalp actinic keratosis. Br J Dermatol; 2007 Jul;157(1):87-91
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized, double-blind, prospective study to compare topical 5-aminolaevulinic acid methylester with topical 5-aminolaevulinic acid photodynamic therapy for extensive scalp actinic keratosis.
  • BACKGROUND: 5-aminolaevlinic acid methylester (MAL) and 5-aminolaevulinic acid (ALA) photodynamic therapy (PDT) are both effective treatment options for actinic keratosis (AK).
  • While MAL is significantly more expensive than ALA, no studies have directly compared their efficacy in the treatment of extensive scalp AK.
  • OBJECTIVES: To compare the efficacy and adverse effects of MAL-PDT with ALA-PDT in the treatment of scalp AK.
  • METHODS: Sixteen male patients aged 59-87 years with extensive scalp AK were randomized into a double-blind, split-scalp prospective study.
  • A blinded observer assessed efficacy comparing AK counts before and 1 month after treatment.
  • There was a mean reduction from baseline in AK counts with the use of ALA-PDT of 6.2 +/- 1.9 compared with 5.6 +/- 3.2 with MAL-PDT (P = 0.588).
  • CONCLUSIONS: This study demonstrates that both ALA-PDT and MAL-PDT result in a significant reduction in scalp AK.
  • However, ALA-PDT is more painful than MAL-PDT in the treatment of extensive scalp AK.
  • [MeSH-major] Aminolevulinic Acid / administration & dosage. Keratosis / drug therapy. Photochemotherapy / methods. Photosensitivity Disorders / drug therapy. Photosensitizing Agents / administration & dosage. Scalp Dermatoses / drug therapy

  • MedlinePlus Health Information. consumer health - Dandruff, Cradle Cap, and Other Scalp Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17501954.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


61. Zelickson B, Counters J, Coles C, Selim M: Light patch: preliminary report of a novel form of blue light delivery for the treatment of actinic keratosis. Dermatol Surg; 2005 Mar;31(3):375-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Light patch: preliminary report of a novel form of blue light delivery for the treatment of actinic keratosis.
  • OBJECTIVE: To evaluate a novel light patch formulated for blue light delivery and topical activation of gamma-aminolevulinic acid (ALA) during photodynamic therapy for the treatment of actinic keratosis (AK).
  • MATERIALS AND METHODS: Ten volunteers with past unsuccessful treatment of AK were enrolled.
  • Areas with AK lesions were treated with 20% ALA (Levulan) for an incubation period of 1 hour.
  • The percentage of visible AK lesions cleared at the 3-month follow-up determined therapeutic efficacy.
  • CONCLUSION: Preliminary results show that the blue light patch is a potentially safe, effective, and alternative method for light delivery and topical ALA activation during photodynamic therapy of AK.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Keratosis / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15841647.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


62. Padilla RS, Sebastian S, Jiang Z, Nindl I, Larson R: Gene expression patterns of normal human skin, actinic keratosis, and squamous cell carcinoma: a spectrum of disease progression. Arch Dermatol; 2010 Mar;146(3):288-93
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression patterns of normal human skin, actinic keratosis, and squamous cell carcinoma: a spectrum of disease progression.
  • OBJECTIVES: To identify and compare the gene expression profiles of actinic keratosis (AK) and squamous cell carcinoma (SCC) and to further clarify critical genetic alterations in the evolution of SCC from normal sun-damaged human skin.
  • Our model was cross-validated using data from a separate study and clearly distinguishes between skin tumors (AK and SCC) and normal skin independent of sun exposure.
  • Genes that were upregulated in AK and SCC were downregulated in normal skin, and genes that were downregulated in AK and SCC were upregulated in normal skin.
  • CONCLUSIONS: The finding of similar differentially expressed genes in AK and SCC confirms that AK is a precursor lesion of SCC and indicates that they are closely related genetically.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. Gene Expression Regulation. Keratosis, Actinic / genetics. RNA / genetics. Skin / metabolism. Skin Neoplasms / genetics
  • [MeSH-minor] Biopsy. Disease Progression. Female. Humans. Male. Oligonucleotide Array Sequence Analysis / methods


63. Christensen E, Bofin A, Gudmundsdóttir I, Skogvoll E: Cytological diagnosis of basal cell carcinoma and actinic keratosis, using Papanicolaou and May-Grünwald-Giemsa stained cutaneous tissue smear. Cytopathology; 2008 Oct;19(5):316-22
Hazardous Substances Data Bank. METHYLENE BLUE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytological diagnosis of basal cell carcinoma and actinic keratosis, using Papanicolaou and May-Grünwald-Giemsa stained cutaneous tissue smear.
  • The aim of this study was to compare and evaluate the diagnostic performance of scrape cytology using two different cytological staining techniques, and to evaluate additional touch imprint cytology, with that of histopathology of basal cell carcinoma (BCC) and actinic keratosis (AK).
  • METHODS: We investigated 50 BCC and 28 AK histologically verified lesions, from 41 and 25 patients, respectively.
  • RESULTS: Scrape cytodiagnosis agreed with histopathology in 48 (Pap) and 47 (MGG) of the 50 BCC cases, and in 26 of 28 (Pap) and 21 of 26 (MGG) AK cases, yielding sensitivities of 96%, 94%, 93% and 81%, respectively.
  • No significant difference in sensitivity between the two staining methods was found but a trend towards higher Pap sensitivity for AK was noted (P = 0.10).
  • Touch imprint cytology confirmed histopathology in 38 of the 77 cases of BCC and AK.
  • CONCLUSION: Cytological diagnosis with either Pap or MGG stain for BCC and AK is reliable, and differentiates well between BCC and AK.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Coloring Agents. Cytodiagnosis / methods. Eosine Yellowish-(YS) / metabolism. Keratosis / diagnosis. Methylene Blue / metabolism. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cytopathology. 2008 Oct;19(5):333-4; author reply 334 [18513288.001]
  • (PMID = 17916094.001).
  • [ISSN] 1365-2303
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / May-Grunwald Giemsa; T42P99266K / Methylene Blue; TDQ283MPCW / Eosine Yellowish-(YS)
  •  go-up   go-down


64. Babilas P, Knobler R, Hummel S, Gottschaller C, Maisch T, Koller M, Landthaler M, Szeimies RM: Variable pulsed light is less painful than light-emitting diodes for topical photodynamic therapy of actinic keratosis: a prospective randomized controlled trial. Br J Dermatol; 2007 Jul;157(1):111-7
MedlinePlus Health Information. consumer health - Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variable pulsed light is less painful than light-emitting diodes for topical photodynamic therapy of actinic keratosis: a prospective randomized controlled trial.
  • BACKGROUND: Photodynamic therapy (PDT) of actinic keratosis (AK) using methylaminolaevulinate (MAL) is an effective and safe treatment option, but the procedure is painful.
  • METHODS: Topical MAL-PDT was conducted in 25 patients with AK (n = 238) who were suitable for two-sided comparison.
  • The overall mean +/- SD infiltration and keratosis score at 3 months after treatment was 0.86 +/- 0.71 (LED system) vs. 1.05 +/- 0.74 (VPL device) (no statistically significant difference; P = 0.292).
  • CONCLUSIONS: VPL used for MAL-PDT is an efficient alternative for the treatment of AK that results in complete remission and cosmesis equivalent to LED irradiation but causes significantly less pain.
  • [MeSH-major] Keratosis / drug therapy. Pain / physiopathology. Photochemotherapy / adverse effects. Photosensitivity Disorders / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17542980.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


65. Nakano A, Tamada Y, Watanabe D, Ishida N, Yamashita N, Kuhara T, Yanagishita T, Kawamura C, Akita Y, Matsumoto Y: A pilot study to assess the efficacy of photodynamic therapy for Japanese patients with actinic keratosis in relation to lesion size and histological severity. Photodermatol Photoimmunol Photomed; 2009 Feb;25(1):37-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot study to assess the efficacy of photodynamic therapy for Japanese patients with actinic keratosis in relation to lesion size and histological severity.
  • BACKGROUND/PURPOSE: Topical 5-aminolevulinic acid (ALA)-based photodynamic therapy (PDT) is effective for actinic keratosis (AK); few studies have examined Oriental patients.
  • The aim of this study is to assess the efficacy of PDT for the treatment of Japanese AK patients classified by lesion size and histological severity.
  • METHODS: Thirty patients with solitary AK lesions were divided into two groups according to diameter: a small lesion group (SL), diameter < or =10 mm and a larger lesion group (LL), diameter >10 mm, and histological severity: Group I (mild and moderate) and Group II (severe).
  • CONCLUSION: The present study demonstrated that ALA-PDT might be useful for treatment of Japanese AK.
  • [MeSH-major] Keratosis, Actinic / drug therapy. Keratosis, Actinic / pathology. Photochemotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19152514.001).
  • [ISSN] 1600-0781
  • [Journal-full-title] Photodermatology, photoimmunology & photomedicine
  • [ISO-abbreviation] Photodermatol Photoimmunol Photomed
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Denmark
  •  go-up   go-down


66. Chen GJ, Feldman SR, Williford PM, Hester EJ, Kiang SH, Gill I, Fleischer AB Jr: Clinical diagnosis of actinic keratosis identifies an elderly population at high risk of developing skin cancer. Dermatol Surg; 2005 Jan;31(1):43-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical diagnosis of actinic keratosis identifies an elderly population at high risk of developing skin cancer.
  • BACKGROUND: Development of actinic keratoses (AK) involves some of the same processes as nonmelanoma skin cancer and may serve as a marker for overall increased risk of skin cancer.
  • OBJECTIVE: The objective of this study was to examine the risk of developing skin cancer in an elderly population with and without AK.
  • RESULTS: Multivariate analysis showed that the risk (odds ratio [OR]) of developing nonmelanoma or melanoma was increased more than sixfold (p < or = .0001) in patients with AK.
  • CONCLUSION: Using data from a nationally representive sample of the Medicare population, this study demonstrates that elders with AK are a population at high risk of developing cutaneous cancer.
  • [MeSH-major] Keratosis / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15720095.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / T32 AR07411
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


67. McLoone N, Donnelly RF, Walsh M, Dolan OM, McLoone S, McKenna K, McCarron PA: Aminolaevulinic acid diffusion characteristics in 'in vitro' normal human skin and actinic keratosis: implications for topical photodynamic therapy. Photodermatol Photoimmunol Photomed; 2008 Aug;24(4):183-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aminolaevulinic acid diffusion characteristics in 'in vitro' normal human skin and actinic keratosis: implications for topical photodynamic therapy.
  • BACKGROUND: The response rate of aminolaevulinic acid (ALA)-based photodynamic therapy (PDT) in certain subtypes of actinic keratosis (AK), such as hypertrophic and hyperkeratotic lesions, is variable, an effect attributable to a supposed lack of ALA penetration.
  • A detailed and depth-related profile of spatial ALA permeation in AK following drug administration would lead to a greater understanding of concentrations achievable before protoporphyrin IX biosynthesis and subsequent PDT.
  • METHODS: ALA penetration through excised normal human skin (NS) and AK lesions was evaluated using a cryostatic sectioning technique and radio-isotope counting following drug delivery using a novel, bioadhesive patch, loaded with 19, 38 or 50 mg/cm(2) ALA.
  • RESULTS: Distinct differences in ALA concentration with respect to depth between AK and NS samples were shown, particularly within the superficial layers of the tissue structure, down to a depth of 1.0 mm.
  • Patch application times were shown to influence ALA concentrations in tissue, but there was no clear correlation between ALA penetration in AK lesions taken from different body locations and from patients of different age.
  • CONCLUSIONS: Sizable variation in ALA concentration was a prominent feature of profiles through AK lesions, which may explain the variation of observed protoporphyrin IX production seen in the clinical implementation of AK PDT.
  • That said, the results of this study show sufficient ALA penetration to a depth of 1.0 mm, which should be satisfactory for successful treatment of the majority of non-hyperkeratotic, hypertrophic AK using patch-based delivery methods.
  • [MeSH-major] Aminolevulinic Acid / pharmacokinetics. Keratosis / metabolism. Photosensitizing Agents / pharmacokinetics. Skin / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18717959.001).
  • [ISSN] 1600-0781
  • [Journal-full-title] Photodermatology, photoimmunology & photomedicine
  • [ISO-abbreviation] Photodermatol Photoimmunol Photomed
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


68. Ooi T, Barnetson RS, Zhuang L, McKane S, Lee JH, Slade HB, Halliday GM: Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial. Br J Dermatol; 2006 Jan;154(1):72-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial.
  • BACKGROUND: Imiquimod 5% cream is a topically applied immune response modifier that has been shown to give effective treatment of actinic keratosis (AK).
  • OBJECTIVES: To determine the nature of cellular infiltrates induced by the application of imiquimod to AK lesions and to study cells involved in the cutaneous immune response.
  • Each patient had punch biopsies of two distinct AK lesions: a lesion was biopsied before treatment to obtain baseline biomarker levels, and a different lesion was biopsied after 2 weeks of treatment.
  • Complete clearance of all treated AK lesions was achieved in five of 11 (45%) imiquimod patients and in none of six vehicle patients.
  • [MeSH-major] Aminoquinolines / therapeutic use. Dendritic Cells / drug effects. Keratosis / drug therapy. Photosensitivity Disorders / drug therapy. T-Lymphocyte Subsets / drug effects

  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16403097.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Biomarkers; 0 / Interferon Inducers; 99011-02-6 / imiquimod
  •  go-up   go-down


69. Szeimies RM, Radny P, Sebastian M, Borrosch F, Dirschka T, Krähn-Senftleben G, Reich K, Pabst G, Voss D, Foguet M, Gahlmann R, Lübbert H, Reinhold U: Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study. Br J Dermatol; 2010 Aug;163(2):386-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study.
  • BACKGROUND: Photodynamic therapy (PDT) with 5-aminolaevulinic acid (ALA) provides a therapeutic option for the treatment of actinic keratosis (AK).
  • A new stable nanoemulsion-based ALA formulation, BF-200 ALA, is currently in clinical development for PDT of AK.
  • OBJECTIVES: To evaluate the efficacy and safety of PDT of AK with BF-200 ALA.
  • A total of 122 patients with four to eight mild to moderate AK lesions on the face and/or the bald scalp were included in eight German study centres.
  • CONCLUSIONS: BF-200 ALA is a very effective new formulation for the treatment of AK with PDT.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Keratosis, Actinic / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Dermatol. 2010 Aug;163(2):236-7 [20666768.001]
  • (PMID = 20518784.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


70. Annemans L, Caekelbergh K, Roelandts R, Boonen H, Leys C, Nikkels AF, van Den Haute V, van Quickenborne L, Verhaeghe E, Leroy B: Real-life practice study of the clinical outcome and cost-effectiveness of photodynamic therapy using methyl aminolevulinate (MAL-PDT) in the management of actinic keratosis and basal cell carcinoma. Eur J Dermatol; 2008 Sep-Oct;18(5):539-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Real-life practice study of the clinical outcome and cost-effectiveness of photodynamic therapy using methyl aminolevulinate (MAL-PDT) in the management of actinic keratosis and basal cell carcinoma.
  • Clinical trials have shown that photodynamic therapy using methyl aminolevulinate (MAL-PDT) is an effective treatment for actinic keratosis (AK), and nodular and superficial basal cell carcinoma (nBCC and sBCC) unsuitable for other available therapies.
  • The objectives of this prospective, observational, one arm study were (i) to verify in a real-life practice study the results obtained in previous clinical trials with MAL-PDT in the treatment of AK, nBCC and sBCC;.
  • Patients with AK and/or BCC were selected according to Belgian reimbursement criteria for treatment with MAL-PDT.
  • Data were collected from 247 patients (117 AK, 130 BCC).
  • A complete clinical response was obtained for 83% of AK (85/102) and BCC (97/116) patients.
  • A good or excellent cosmetic outcome was obtained for 95% of AK patients and 93% of BCC patients.
  • Total cost of care per patient was euro 381 for AK, euro 318 for nBCC, and euro 298 for sBCC.
  • Total cost per lesion was euro 58 for AK (identical to model prediction), euro 316 for nBCC and euro 178 for sBCC (both within 20% of model prediction).
  • Costs calculated from this study confirm predicted cost-effectiveness in the original model for MAL-PDT in the management of AK and BCC.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / economics. Keratosis, Actinic / drug therapy. Keratosis, Actinic / economics. Photochemotherapy / economics. Photosensitizing Agents / economics. Photosensitizing Agents / therapeutic use. Skin Neoplasms / drug therapy. Skin Neoplasms / economics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18693157.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


71. Brasanac D, Boricic I, Todorovic V, Tomanovic N, Radojevic S: Cyclin A and beta-catenin expression in actinic keratosis, Bowen's disease and invasive squamous cell carcinoma of the skin. Br J Dermatol; 2005 Dec;153(6):1166-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclin A and beta-catenin expression in actinic keratosis, Bowen's disease and invasive squamous cell carcinoma of the skin.
  • BACKGROUND: Actinic keratosis (AK) has been defined as a precancerous lesion or an early phase in the evolution of squamous cell carcinoma (SCC) and histological changes seen in the individual cells of an AK are indistinguishable from those seen in SCC, which invade the dermis.
  • OBJECTIVES: To determine cyclin A and beta-catenin expression pattern in cutaneous SCC and in in situ lesions classified as keratinocytic intraepidermal neoplasia (KIN) and, using traditional terms, as AK and Bowen's disease (BD), and to analyse it in relation to SCC differentiation, diameter and thickness.
  • On histological examination, 53 lesions were diagnosed as AK, 16 as BD and 41 as SCC-11 well differentiated (WD), 16 moderately differentiated (MD) and 14 poorly differentiated (PD).
  • RESULTS: Diffuse cyclin A presence was observed more frequently in BD than in AK (P < 0.0001) or SCC (P = 0.0002), and in SCC-PD compared with SCC-WD (P < 0.0001) or SCC-MD (P = 0.0003).
  • Cyclin A LI was significantly lower (P < 0.05) in AK than in BD or SCC, but no difference between BD and SCC was found, and LI in BD was even higher than in SCC-WD or SCC-MD, while analysis regarding SCC differentiation and KIN classification revealed the same correlation as for the cyclin A distribution.
  • Reduced or absent beta-catenin membranous staining was found in 90 cases (81.8%), more often in SCC than in AK (P = 0.03) or in AK and BD grouped together (P = 0.02).
  • Diffuse loss of membranous beta-catenin staining showed 36 lesions (32.7%), more frequently SCC than AK (P = 0.003) or AK and BD grouped (P = 0.006), as well as SCC-PD compared with SCC-WD (P = 0.01) and SCC-MD (P = 0.03), whereas all KIN comparisons remained nonsignificant.
  • CONCLUSIONS: Cyclin A LI showed greater difference between AK and BD than between BD and SCC, suggesting that increased proliferation (measured by cyclin A LI) characterizes progression of in situ lesions from AK to BD, whereas reduced beta-catenin expression separates more clearly SCC from the in situ lesions.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Cyclin A / metabolism. Keratosis / metabolism. Skin Neoplasms / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bowen's Disease / metabolism. Bowen's Disease / pathology. Disease Progression. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Proteins / metabolism. Precancerous Conditions / metabolism. Precancerous Conditions / pathology


72. Gupta AK, Davey V, Mcphail H: Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: Critical review and meta-analysis of efficacy studies. J Cutan Med Surg; 2005 Oct;9(5):209-14
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: Critical review and meta-analysis of efficacy studies.
  • BACKGROUND: Actinic keratosis lesions occur frequently on sun-exposed skin of Caucasians.
  • Topical therapies are useful alternatives to cryotherapy for treating diffuse actinic damage and a number of preparations have been developed for treating actinic keratosis.
  • OBJECTIVES: A cumulative meta-analysis was performed to determine the efficacy of imiquimod 5% cream, which presents a new alternative topical therapy for actinic keratosis, and to compare it to 5-fluorouracil for the treatment of actinic keratosis lesions of the face and scalp.
  • METHODS: We searched MEDLINE (1966 to October 2004) for relevant studies evaluating the efficacy of actinic keratosis topical agents imiquimod and 5-fluorouracil (0.5%, 1%, and 5%).
  • Studies also required a well-defined treatment duration and followup period, with the primary efficacy variable being the complete (100%) clearance of all actinic keratosis lesions defined as the proportion of patients at followup with no clinically visible lesions in the treatment area.
  • CONCLUSIONS: The results of this meta-analysis show that both imiquimod and 5-fluorouracil are effective methods for the treatment of actinic keratosis and provide a useful alternative to cryotherapy.
  • However, this analysis suggests that imiquimod may have higher efficacy than 5-fluorouracil for actinic keratosis lesions located on the face and scalp and therefore provides another option to dermatologists.
  • [MeSH-major] Aminoquinolines / therapeutic use. Fluorouracil / therapeutic use. Immunosuppressive Agents / therapeutic use. Interferon Inducers / therapeutic use. Keratosis / drug therapy. Photosensitivity Disorders / drug therapy

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16502198.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Immunosuppressive Agents; 0 / Interferon Inducers; 0 / Ointments; P1QW714R7M / imiquimod; U3P01618RT / Fluorouracil
  • [Number-of-references] 55
  •  go-up   go-down


73. Holmes C, Foley P, Freeman M, Chong AH: Solar keratosis: epidemiology, pathogenesis, presentation and treatment. Australas J Dermatol; 2007 May;48(2):67-74; quiz 75-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solar keratosis: epidemiology, pathogenesis, presentation and treatment.
  • Solar keratosis is a common problem encountered by dermatologists, particularly in Australia.
  • Solar keratosis is most commonly found on sun-exposed areas such as the scalp, face and forearms.
  • Solar keratosis usually presents as a discrete, variably erythematous and irregular lesion with a scaly surface.
  • Although the exact rate of malignant transformation to squamous cell carcinoma is unknown, the majority of squamous cell carcinomas appear to arise from within solar keratosis.
  • For this reason, solar keratosis is commonly treated and, consequently, an increasing number of therapeutic options is now available.
  • [MeSH-major] Environmental Exposure / analysis. Keratosis / diagnosis. Keratosis / therapy. Ultraviolet Rays
  • [MeSH-minor] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Australia / epidemiology. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / therapy. Cryotherapy. Diagnosis, Differential. Disease Progression. Humans. Photosensitizing Agents / therapeutic use. Precancerous Conditions / diagnosis. Precancerous Conditions / epidemiology. Precancerous Conditions / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17535191.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Photosensitizing Agents
  • [Number-of-references] 89
  •  go-up   go-down


74. Makdsi F, Deversa R: Inflammation of actinic keratosis with combination of alkylating and taxane agents: a case report. Cases J; 2009;2:6946

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammation of actinic keratosis with combination of alkylating and taxane agents: a case report.
  • This combination has not been documented to date to cause an inflammation of a preexisting actinic keratosis.
  • One previous report has described inflammation of AK lesions after the use of docetaxel alone.
  • CASE PRESENTATION: We report a case of a 54-year-old male with a history of untreated actinic keratosis and lung cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Dermatol. 2008 Jun;144(6):779-82 [18559769.001]
  • [Cites] Oncol Rep. 2007 Sep;18(3):581-4 [17671704.001]
  • [Cites] Arch Dermatol. 2003 Jan;139(1):77-81 [12533171.001]
  • [Cites] J Am Acad Dermatol. 1999 Mar;40(3):367-98; quiz 399-400 [10071309.001]
  • [Cites] Arch Dermatol. 1995 Feb;131(2):202-6 [7857119.001]
  • [Cites] J Am Acad Dermatol. 2006 Nov;55(5 Suppl):S119-20 [17052530.001]
  • (PMID = 19829884.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2740192
  •  go-up   go-down


75. Jacobs RJ, Phillips G: Basal cell carcinoma mistaken for actinic keratosis. Clin Exp Optom; 2006 May;89(3):171-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma mistaken for actinic keratosis.
  • Increasing age and UV exposure are well-known associations with precancerous and cancerous skin lesions, including actinic (solar) keratosis, and squamous and basal cell carcinomata.
  • This report describes a patient with a facial skin lesion close to an eye that was initially believed to be actinic (solar) keratosis but was subsequently diagnosed as a basal cell carcinoma (BCC).
  • The diagnosis of BCC was helped pre-operatively by manipulation of the surrounding facial skin, which revealed the characteristic rolled edges and telangiectasis.
  • The lesion was surgically excised and the diagnosis of basal cell carcinoma was confirmed by pathological examination.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Eyelid Neoplasms / pathology. Keratosis / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Follow-Up Studies. Humans. Male. Middle Aged. Sunlight / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16637973.001).
  • [ISSN] 0816-4622
  • [Journal-full-title] Clinical & experimental optometry
  • [ISO-abbreviation] Clin Exp Optom
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


76. Ulrich M, Forschner T, Röwert-Huber J, González S, Stockfleth E, Sterry W, Astner S: Differentiation between actinic keratoses and disseminated superficial actinic porokeratoses with reflectance confocal microscopy. Br J Dermatol; 2007 May;156 Suppl 3:47-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation between actinic keratoses and disseminated superficial actinic porokeratoses with reflectance confocal microscopy.
  • BACKGROUND: Clinical differentiation between actinic keratosis (AK) and disseminated superficial actinic porokeratosis (DSAP) may pose a significant challenge, and histological evaluation is often also required for diagnosis.
  • Distinct morphological features can be distinguished upon histopathological examination, but the use of non-invasive tools, such as reflectance confocal microscopy (RCM), may be an eligible alternative for confirmation of diagnosis.
  • OBJECTIVES: The aim of this study was to determine the relevant RCM criteria for the identification of disseminated superficial actinic porokeratoses (DSAPs) and to define distinguishing criteria for DSAPs compared with actinic keratosis (AKs).
  • PATIENTS/METHODS: A total of 20 patients with a clinical diagnosis of AK or DSAP were included in this study.
  • RESULTS: Cellular and nuclear atypia, inflammation, spongiosis, parakeratosis and changes in epidermal architecture were present in both lesion types (i.e.
  • However, further studies are warranted to assess the sensitivity and specificity of RCM in the diagnosis of DSAP.
  • [MeSH-major] Keratosis / pathology. Porokeratosis / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Feasibility Studies. Humans. Microscopy, Confocal / methods

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488407.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


77. Nelson CG, Spencer J, Nelson CG Jr: A single-arm, open-label efficacy and tolerability study of diclofenac sodium 3% gel for the treatment of actinic keratosis of the upper and lower lip. J Drugs Dermatol; 2007 Jul;6(7):712-7
Hazardous Substances Data Bank. DICLOFENAC .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single-arm, open-label efficacy and tolerability study of diclofenac sodium 3% gel for the treatment of actinic keratosis of the upper and lower lip.
  • OBJECTIVES AND METHODS: This study is an evaluation of patients diagnosed with actinic keratosis (AK) lesions of the upper and lower lip (both cutaneous and mucosal surfaces), with at least one lesion on the vermilion (mucosal) lip.
  • CONCLUSION: The application of diclofenac sodium 3% gel provides an effective approach for the treatment of AK of the lip.
  • The cure rate reported in this study for AK of the lip was similar to that of diclofenac sodium 3% gel for AK on skin elsewhere on the body, and has a low incidence of irritation and other adverse reactions, as well as a high rate of patient satisfaction.
  • [MeSH-major] Diclofenac / therapeutic use. Keratosis / drug therapy. Lip Diseases / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17763595.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Gels; 144O8QL0L1 / Diclofenac
  •  go-up   go-down


78. Radakovic-Fijan S, Blecha-Thalhammer U, Kittler H, Hönigsmann H, Tanew A: Efficacy of 3 different light doses in the treatment of actinic keratosis with 5-aminolevulinic acid photodynamic therapy: a randomized, observer-blinded, intrapatient, comparison study. J Am Acad Dermatol; 2005 Nov;53(5):823-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of 3 different light doses in the treatment of actinic keratosis with 5-aminolevulinic acid photodynamic therapy: a randomized, observer-blinded, intrapatient, comparison study.
  • BACKGROUND: Topical 5-aminolevulinic acid-based photodynamic therapy (ALA-PDT) has been established in recent years as an effective treatment for disseminated actinic keratosis (AK).
  • As yet, however, data are lacking to define the optimal light dose for activation of ALA-induced protoporphyrin IX in AK.
  • OBJECTIVE: In the present study our purpose was to compare the efficacy and tolerability of 3 different doses of red light for ALA-PDT of AK.
  • After occlusion for 4 hours with 20% ALA, one AK each was irradiated at random with a single dose of 70, 100, or 140 J/cm2.
  • CONCLUSION: Our results indicate that a red light dose of 70 J/cm2 may be sufficient for effective topical ALA-PDT of disseminated, mild to moderate AK on the face and scalp.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Keratosis / etiology. Photochemotherapy. Photosensitivity Disorders / drug therapy. Photosensitizing Agents / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16243131.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


79. Schwartz RA, Bridges TM, Butani AK, Ehrlich A: Actinic keratosis: an occupational and environmental disorder. J Eur Acad Dermatol Venereol; 2008 May;22(5):606-15
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Actinic keratosis: an occupational and environmental disorder.
  • Solar ultraviolet light electromagnetic waves are a known environmental carcinogenic agent closely associated with the development of skin cancer in light-complexioned individuals.
  • We will review the topic of actinic keratoses among these individuals as this common rudimentary form of superficial cutaneous squamous cell carcinoma is explored in greater detail.
  • [MeSH-major] Carcinoma, Squamous Cell / etiology. Environmental Exposure / adverse effects. Keratosis / etiology. Occupational Exposure / adverse effects. Skin Neoplasms / etiology
  • [MeSH-minor] Disease Progression. Female. Humans. Male. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18410618.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 79
  •  go-up   go-down


80. Ulrich M, Drecoll U, Stockfleth E: Emerging drugs for actinic keratosis. Expert Opin Emerg Drugs; 2010 Dec;15(4):545-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emerging drugs for actinic keratosis.
  • IMPORTANCE OF THE FIELD: Actinic keratoses (AK) represent a worldwide problem with continuously increasing incidence.
  • AK are characterized by a proliferation of atypical keratinocytes limited to the epidermis, but they may develop into invasive squamous cell carcinoma.
  • AREAS COVERED IN THIS REVIEW: An overview about current treatment modalities for AK including, among others, their mechanism of action, application scheme and common side effects.
  • WHAT THE READER WILL GAIN: The reader of this review will be informed about all current treatment modalities for AK.
  • Furthermore, the reader will gain knowledge about ongoing research in this field and novel topical drugs for the treatment of AK.
  • TAKE HOME MESSAGE: Many treatment modalities are available for the treatment of AK.
  • In this regard, several topical drugs have been approved for AK, differing in clearance rates, side effects, application and cost.
  • Research is continuing aiming in the development of the "ideal" treatment of AK which combines high clearance rates with few side effects, short treatment duration and low costs.
  • [MeSH-major] Drug Design. Keratosis, Actinic / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20670178.001).
  • [ISSN] 1744-7623
  • [Journal-full-title] Expert opinion on emerging drugs
  • [ISO-abbreviation] Expert Opin Emerg Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


81. Korman N, Moy R, Ling M, Matheson R, Smith S, McKane S, Lee JH: Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol; 2005 Apr;141(4):467-73
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials.
  • OBJECTIVE: To evaluate the efficacy and safety of 5% imiquimod cream compared with vehicle in the treatment of actinic keratosis (AK).
  • PATIENTS: Four hundred ninety-two patients, 18 years and older, with 4 to 8 AK lesions in a 25-cm(2) treatment area on the face or the balding scalp were randomized; an additional 162 patients underwent screening but were ineligible.
  • MAIN OUTCOME MEASUREMENTS: Complete clearance rate (proportion of patients at the 8-week posttreatment visit with no clinically visible AK lesions in the treatment area), partial clearance rate (proportion of patients at the 8-week posttreatment visit with a >/=75% reduction in the number of baseline AK lesions in the treatment area), and frequency and severity of adverse events and local skin reactions were measured.
  • CONCLUSION: The 5% imiquimod cream dosed 3 times weekly for 16 weeks is safe and effective for the treatment of AK.
  • [MeSH-major] Aminoquinolines / therapeutic use. Keratosis / drug therapy. Keratosis / pathology. Precancerous Conditions / pathology

  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15837864.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Ointments; 99011-02-6 / imiquimod
  •  go-up   go-down


82. Dornelas MT, Rodrigues MF, Machado DC, Gollner AM, Ferreira AP: [Expression of cell proliferation and apoptosis biomarkers in skin spinocellular carcinoma and actinic keratosis]. An Bras Dermatol; 2009 Sep-Oct;84(5):469-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of cell proliferation and apoptosis biomarkers in skin spinocellular carcinoma and actinic keratosis].
  • [Transliterated title] Expressão de marcadores de proliferação celular e apoptose no carcinoma espinocelular de pele e ceratose actínica.
  • In many cases, before the onset of the carcinoma, there might be a precursor lesion--actinic keratosis, which can develop into squamous cell carcinoma.
  • OBJECTIVE: To evaluate the expression of markers of cell proliferation (PCNA, Ki-67) and apoptosis (p53,Bcl-2) in patients with squamous cell carcinoma and actinic keratosis.
  • METHOD: We studied samples from 30 patients, ten patients of squamous cell carcinoma, ten with actinic keratosis and ten lesion-free samples from blepharoplasty.
  • Bcl-2 was expressed at low intensity in six cases of actinic keratosis in the skin from blepharoplasty and negative in cases of squamous cell carcinoma.
  • Ki-67 showed variable expression in cases of keratosis and carcinoma and negative in the skin from the eyelid.
  • Thus, expression of p53 and Bcl-2 in patients with actinic keratosis indicates cell immortalization.
  • [MeSH-major] Apoptosis. Carcinoma, Squamous Cell / pathology. Cell Proliferation. Keratosis, Actinic / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20098848.001).
  • [ISSN] 1806-4841
  • [Journal-full-title] Anais brasileiros de dermatologia
  • [ISO-abbreviation] An Bras Dermatol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


83. Gebauer K, Shumack S, Cowen PS: Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial. Br J Dermatol; 2009 Oct;161(4):897-903
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial.
  • BACKGROUND: Clinical studies in cutaneous conditions other than actinic keratosis (AK) have revealed that the safety and efficacy profile of imiquimod is influenced by dosing frequency.
  • OBJECTIVES: To evaluate dosing frequency response of imiquimod 5% for treatment of AK.
  • [MeSH-major] Adjuvants, Immunologic / administration & dosage. Aminoquinolines / administration & dosage. Hand Dermatoses / drug therapy. Keratosis, Actinic / drug therapy. Precancerous Conditions / drug therapy

  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19545297.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 99011-02-6 / imiquimod
  •  go-up   go-down


84. Fernández-Guarino M, Harto A, Jaén P: [Studies of methyl aminolevulinate photodynamic therapy for actinic keratosis]. Actas Dermosifiliogr; 2010 May;101(4):315-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Studies of methyl aminolevulinate photodynamic therapy for actinic keratosis].
  • [Transliterated title] Terapia fotodinámica: estudios con metilaminolevulinato en queratosis actínicas.
  • Photodynamic therapy (PDT) for the treatment of actinic keratosis has been shown to be effective and safe in large clinical trials published in the last 5 years.
  • However, evidence has since emerged that raises questions or that introduces new issues, such as the management of field cancerization, fluorescence diagnosis and results in transplant recipients.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Keratosis, Actinic / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20487686.001).
  • [ISSN] 1578-2190
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  • [Number-of-references] 49
  •  go-up   go-down


85. Sherry SD, Miles BA, Finn RA: Long-term efficacy of carbon dioxide laser resurfacing for facial actinic keratosis. J Oral Maxillofac Surg; 2007 Jun;65(6):1135-9
Hazardous Substances Data Bank. Carbon dioxide .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term efficacy of carbon dioxide laser resurfacing for facial actinic keratosis.
  • PURPOSE: To evaluate the efficacy and long-term effectiveness of carbon dioxide laser resurfacing in the treatment of patients with facial actinic keratosis.
  • PATIENTS AND METHODS: A retrospective chart analysis was conducted of 31 patients who underwent full face carbon dioxide laser resurfacing for facial actinic keratosis from July 1998 to November 2002.
  • The average actinic keratosis free period, excluding 2 deceased patients, was 27.4 months.
  • CONCLUSION: Carbon dioxide laser resurfacing is an effective tool in the management of patients with facial actinic keratosis.
  • [MeSH-major] Facial Dermatoses / surgery. Keratosis / surgery. Laser Therapy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17517297.001).
  • [ISSN] 0278-2391
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 142M471B3J / Carbon Dioxide
  •  go-up   go-down


86. Shoimer I, Rosen N, Muhn C: Current management of actinic keratoses. Skin Therapy Lett; 2010 May;15(5):5-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current management of actinic keratoses.
  • An actinic keratosis (AK) is a pre-malignant cutaneous lesion that frequently manifests in sun-exposed areas of the skin as a small, rough, scaly erythematous papule.
  • [MeSH-major] Carcinoma, Squamous Cell / prevention & control. Keratosis, Actinic / therapy. Skin Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20505896.001).
  • [ISSN] 1201-5989
  • [Journal-full-title] Skin therapy letter
  • [ISO-abbreviation] Skin Therapy Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antineoplastic Agents; 144O8QL0L1 / Diclofenac; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil
  •  go-up   go-down


87. Larkö O: The current options in the management of actinic keratosis. G Ital Dermatol Venereol; 2009 Aug;144(4):445-52
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The current options in the management of actinic keratosis.
  • Actinic keratosis is a precursor for squamous cell skin cancer.
  • For single actinic keratoses, cryo surgery is recommended.
  • For widespread actinic keratoses, imiquimod, photodynamic therapy (PDT) or 5-FU may be used.
  • Consequently, cryo surgery for single actinic keratoses and PDT for widespread actinic keratoses should primarily be recommended.
  • [MeSH-major] Keratosis, Actinic / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19755948.001).
  • [ISSN] 0392-0488
  • [Journal-full-title] Giornale italiano di dermatologia e venereologia : organo ufficiale, Società italiana di dermatologia e sifilografia
  • [ISO-abbreviation] G Ital Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


88. Hafner C, Vogt T: Seborrheic keratosis. J Dtsch Dermatol Ges; 2008 Aug;6(8):664-77
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for seborrheic keratosis .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seborrheic keratosis.
  • Seborrheic keratosis is one of the most common skin tumors.
  • Despite its frequency, many aspects of seborrheic keratosis remain elusive.
  • In the last years new molecular genetic insights into seborrheic keratoses have been gained.
  • The current knowledge about seborrheic keratosis with respect to epidemiology, pathogenesis, diagnosis and therapy is summarized.
  • [MeSH-major] Clinical Trials as Topic / trends. Keratosis, Seborrheic / diagnosis. Keratosis, Seborrheic / therapy

  • Genetic Alliance. consumer health - Keratosis, seborrheic.
  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18801147.001).
  • [ISSN] 1610-0387
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] eng; ger
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 11
  •  go-up   go-down


89. Schäfer-Korting M, Höltje M, Korting HC, Höltje HD: Innovative agents for actinic keratosis and nanocarriers enhancing skin penetration. Skin Pharmacol Physiol; 2010;23(1):6-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Innovative agents for actinic keratosis and nanocarriers enhancing skin penetration.
  • Actinic keratosis and cutaneous squamous cell carcinoma are of increasing importance with aging and increased ultraviolet light exposure in Western societies.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Keratosis, Actinic / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 S. Karger AG, Basel.
  • (PMID = 20090403.001).
  • [ISSN] 1660-5535
  • [Journal-full-title] Skin pharmacology and physiology
  • [ISO-abbreviation] Skin Pharmacol Physiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


90. Kvlividze O, Gogiashvili L, Burkadze G: The characteristics of human papillomavirus expression and cell proliferation in actinic keratosis and Bowen's disease of the skin. Georgian Med News; 2006 Jul;(136):108-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The characteristics of human papillomavirus expression and cell proliferation in actinic keratosis and Bowen's disease of the skin.
  • The aim of our study was to elucidate the characteristics of HPV expression and cell proliferation in actinic keratosis and Bowen's disease of the skin.
  • We examined immunocompetent patients with premalignant lesions of the skin such as actinic keratosis and Bowen's disease.
  • Actinic keratosis and Bowen's disease failed to show the specific clinical features, therefore, they can not be diagnosed based on clinical signs only and morphological examination seems to be mandatory.
  • The immunohistochemical study has showed that in both actinic keratosis and Bowen's disease HPV was positive in 60%, and 40% were HPV-negative suggesting the similar incidence of HPV infection in these premalignant lesions.
  • Our results suggest that HPV(+)/p53(+) types of actinic keratosis and Bowen's disease are characterized by higher proliferation activity in comparison to HPV(-)/p53(+) types, and expression of Bcl-2 is associated with HPV-negativity, therefore, these premalignant lesions of the skin require immunohistochemical examination with evaluation of expressions of human papillomavirus, proliferation marker PCNA and anti-apoptotic protein Bcl-2.
  • The differential diagnosis of actinic keratosis and Bowen's disease should be based on the following immunohistochemical criteria: incidences of positivity for p53, Bcl-2 and PCNA are similar, but expression intensity and anatomical localization are different: their expressions are higher in Bowen's disease, positive cells are found primarily in upper epidermis in actinic keratosis, while whole epithelium is involved in Bowen's disease.
  • [MeSH-major] Antibodies, Viral / immunology. Bowen's Disease / virology. Human papillomavirus 6 / immunology. Photosensitivity Disorders / virology. Skin Neoplasms / virology

  • Genetic Alliance. consumer health - Bowen's Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16905862.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Georgia (Republic)
  • [Chemical-registry-number] 0 / Antibodies, Viral
  •  go-up   go-down


91. Smits T, Moor AC: New aspects in photodynamic therapy of actinic keratoses. J Photochem Photobiol B; 2009 Sep 4;96(3):159-69
SciCrunch. DrugBank: Data: Chemical .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New aspects in photodynamic therapy of actinic keratoses.
  • Photodynamic therapy (PDT) using 5-aminolevulinic acid (5-ALA) or its methyl ester (MAL) is a very effective method to treat actinic keratosis (AK).
  • [MeSH-major] Keratosis, Actinic / drug therapy. Photochemotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19592269.001).
  • [ISSN] 1873-2682
  • [Journal-full-title] Journal of photochemistry and photobiology. B, Biology
  • [ISO-abbreviation] J. Photochem. Photobiol. B, Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Protoporphyrins; 0 / delta-aminolevulinic acid methyl ester; 553-12-8 / protoporphyrin IX; 88755TAZ87 / Aminolevulinic Acid
  • [Number-of-references] 132
  •  go-up   go-down


92. Bon-Mardion M, Poulalhon N, Balme B, Thomas L: Ungual seborrheic keratosis. J Eur Acad Dermatol Venereol; 2010 Sep;24(9):1102-4
MedlinePlus Health Information. consumer health - Nail Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ungual seborrheic keratosis.
  • BACKGROUND/OBJECTIVES: Seborrheic keratoses are ubiquitous benign epithelial skin tumours.
  • We report herein the case of a seborrheic keratosis of the nail bed with typical histological features.
  • The diagnosis of typical seborrheic keratosis of the nail bed was made on histological examination.
  • CONCLUSION: To our knowledge, this is the first report of a typical, histologically documented seborrheic keratosis of the nail bed.
  • Therefore, this condition should be added to the differential diagnosis of acquired longitudinal leukoxanthonychia.
  • [MeSH-major] Keratosis, Seborrheic / diagnosis. Nail Diseases / diagnosis

  • Genetic Alliance. consumer health - Keratosis, seborrheic.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20180892.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


93. Ulrich M, Maltusch A, Röwert-Huber J, González S, Sterry W, Stockfleth E, Astner S: Actinic keratoses: non-invasive diagnosis for field cancerisation. Br J Dermatol; 2007 May;156 Suppl 3:13-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Actinic keratoses: non-invasive diagnosis for field cancerisation.
  • BACKGROUND: Actinic keratoses (AKs) are among the most common cutaneous malignancies and have previously been classified as in situ squamous cell carcinoma (SCC) with reported progression rates of up to 20% over 10 years.
  • In vivo reflectance confocal microscopy (RCM) has been used for evaluation of the morphological features of non-melanoma skin cancer (NMSC) and RCM evaluation parameters for the diagnosis of AKs have been reported.
  • PATIENTS/METHODS: Forty four Caucasians (SPT I-III) with a minimum of one actinic keratosis (AK) lesion were included in this study.
  • Following blinded evaluation by two independent investigators, 97.7% of all skin samples were identified as AK using RCM.
  • 2.3% were incorrectly identified as normal skin by RCM, while routine histology showed features consistent with AK.
  • CONCLUSIONS: Reflectance confocal microscopy may be a feasible alternative in the diagnosis of AK and may aid in the differentiation against normal skin, as well as in the detection of subclinical disease.
  • [MeSH-major] Keratosis / pathology. Precancerous Conditions / pathology. Skin / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Disease Progression. Humans. Microscopy, Confocal / methods. Sunlight / adverse effects

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488401.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


94. Rossi R, Calzavara-Pinton PG, Giannetti A, Peserico A, Santucci M, Vena GA, Lotti T: Italian guidelines and therapeutic algorithm for actinic keratoses. G Ital Dermatol Venereol; 2009 Dec;144(6):713-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Italian guidelines and therapeutic algorithm for actinic keratoses.
  • The prevalence of actinic keratosis (AK) continues to rise among white people throughout the world and it is necessary to increase the level of attention paid to it from a diagnostic and a preventive point of view.
  • Today, AK must be considered an in situ squamous cell carcinoma and as such, must be managed using one of the available approved therapeutic alternatives.
  • [MeSH-major] Keratosis, Actinic / therapy. Practice Guidelines as Topic. Precancerous Conditions / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Algorithms. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / prevention & control. Cryotherapy. Curettage. Dermatologic Agents / therapeutic use. Disease Progression. Electrocoagulation. Female. Humans. Italy / epidemiology. Laser Therapy. Male. Middle Aged. Neoplasms, Radiation-Induced / etiology. Neoplasms, Radiation-Induced / prevention & control. Phototherapy. Prevalence. Risk Factors. Sunscreening Agents. Ultraviolet Rays / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19907409.001).
  • [ISSN] 0392-0488
  • [Journal-full-title] Giornale italiano di dermatologia e venereologia : organo ufficiale, Società italiana di dermatologia e sifilografia
  • [ISO-abbreviation] G Ital Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Dermatologic Agents; 0 / Sunscreening Agents
  •  go-up   go-down


95. Muston D, Downs A, Rives V: An economic evaluation of topical treatments for actinic keratosis. J Dermatolog Treat; 2009;20(5):266-75
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An economic evaluation of topical treatments for actinic keratosis.
  • Actinic keratoses (AK) commonly occur as lesions, in sun-exposed areas.
  • We assessed the cost-effectiveness in 2007 of topical treatments (5-fluorouracil, imiquimod) and photodynamic therapy with methyl aminolevulinate (MAL-PDT) for AK under the perspective of the UK National Health Service (NHS) in England and Wales over two lines of treatment.
  • Based on this model, the costs and effectiveness of MAL-PDT in the UK NHS compare well with other treatments for AK.
  • [MeSH-major] Antineoplastic Agents / economics. Keratosis, Actinic / economics. Keratosis, Actinic / therapy. Photochemotherapy / economics. Photosensitizing Agents / economics

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Dermatolog Treat. 2011 Oct;22(5):298-301 [20666679.001]
  • (PMID = 19421918.001).
  • [ISSN] 1471-1753
  • [Journal-full-title] The Journal of dermatological treatment
  • [ISO-abbreviation] J Dermatolog Treat
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil
  •  go-up   go-down


96. Zalaudek I, Ferrara G, Leinweber B, Mercogliano A, D'Ambrosio A, Argenziano G: Pitfalls in the clinical and dermoscopic diagnosis of pigmented actinic keratosis. J Am Acad Dermatol; 2005 Dec;53(6):1071-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pitfalls in the clinical and dermoscopic diagnosis of pigmented actinic keratosis.
  • Pigmented actinic keratosis and melanoma may exhibit overlapping clinical features, thus representing a diagnostic challenge for dermatologists.
  • We report the clinical and dermoscopic features of two pigmented actinic keratoses to discuss the difficulties in their preoperative differential diagnosis.
  • [MeSH-major] Dermoscopy. Keratosis / diagnosis. Photosensitivity Disorders / diagnosis. Pigmentation Disorders / diagnosis

  • MedlinePlus Health Information. consumer health - Skin Pigmentation Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16310072.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Braathen LR, Paredes BE, Saksela O, Fritsch C, Gardlo K, Morken T, Frølich KW, Warloe T, Solér AM, Ros AM: Short incubation with methyl aminolevulinate for photodynamic therapy of actinic keratoses. J Eur Acad Dermatol Venereol; 2009 May;23(5):550-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short incubation with methyl aminolevulinate for photodynamic therapy of actinic keratoses.
  • BACKGROUND: Photodynamic therapy (PDT) using methyl aminolevulinate (MAL) is an effective first-line treatment for actinic keratoses.
  • OBJECTIVE: This study aims to evaluate the effect of incubation time (1 vs. 3 h), MAL concentration (160 mg/g vs. 80 mg/g) and lesion preparation in the setting of MAL-PDT for treatment of actinic keratosis (AK).
  • SUBJECTS: One hundred and twelve patients with 384 previously untreated AK.
  • RESULTS: For lesions on the face/scalp, lesion complete response rates were 78% for thin AK and 74% for moderately thick AK lesions after 1 h vs. 96% and 87% after 3 h incubation with MAL 160 mg/g.
  • CONCLUSION: MAL-PDT using a 1-h incubation may be sufficient for successful treatment of selected AK lesions.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Keratosis, Actinic / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19415804.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cosmetics; 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


98. Akay BN, Kocyigit P, Heper AO, Erdem C: Dermatoscopy of flat pigmented facial lesions: diagnostic challenge between pigmented actinic keratosis and lentigo maligna. Br J Dermatol; 2010 Dec;163(6):1212-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermatoscopy of flat pigmented facial lesions: diagnostic challenge between pigmented actinic keratosis and lentigo maligna.
  • BACKGROUND: The similarity between clinical pictures of pigmented actinic keratosis (PAK) and lentigo maligna (LM) is well known.
  • The lesions showing one or more dermatoscopic features considered as specific patterns for the diagnosis of LM/LMM, mainly slate-grey to black dots and globules, slate-grey areas, annular-granular pattern, asymmetrical pigmented follicular openings, black blotches, rhomboidal structures, hyperpigmented rim of follicular openings, slate-grey streaks and dark streaks, were included in the study selectively.
  • RESULTS: PAK was diagnosed in 67, LM or LMM in 20 and lichen planus-like keratosis in two lesions, histopathologically.
  • As dermatoscopic diagnosis of a pigmented skin lesion cannot be based on the presence of a single criterion, we may conclude that histopathology still remains the gold standard for correct diagnosis.
  • [MeSH-major] Facial Dermatoses / pathology. Hutchinson's Melanotic Freckle / pathology. Keratosis, Actinic / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dermoscopy. Diagnosis, Differential. Face / pathology. Female. Humans. Male. Middle Aged. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. BJD © 2010 British Association of Dermatologists.
  • (PMID = 21083845.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


99. Quatresooz P, Paquet P, Piérard GE: [Actinic keratosis in tune with field photocarcinogenesis. A revisited concept]. Rev Med Liege; 2010 Nov;65(11):619-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Actinic keratosis in tune with field photocarcinogenesis. A revisited concept].
  • [Transliterated title] La kératose actinique au diapason de la photocarcinogenèse en champs. Un concept revisité.
  • Actinic keratosis should no more be considered as a single neoplasm calling for an individual treatment.
  • The concept of actinic photocarcinogenesis presently turns upside down the perception of skin cancers induced by nonionizing electromagnetic radiations.
  • [MeSH-major] Keratosis, Actinic / etiology. Keratosis, Actinic / therapy. Ultraviolet Rays / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21189527.001).
  • [ISSN] 0370-629X
  • [Journal-full-title] Revue médicale de Liège
  • [ISO-abbreviation] Rev Med Liege
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


100. Brodsky J: Management of benign skin lesions commonly affecting the face: actinic keratosis, seborrheic keratosis, and rosacea. Curr Opin Otolaryngol Head Neck Surg; 2009 Aug;17(4):315-20
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for seborrheic keratosis .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of benign skin lesions commonly affecting the face: actinic keratosis, seborrheic keratosis, and rosacea.
  • RECENT FINDINGS: Actinic keratosis can now be treated with photodynamic therapy or with many topical agents, as alternatives to traditional surgical techniques.
  • Seborrheic keratosis, as well as actinic keratosis and rosacea, are now often treated with laser therapy.
  • [MeSH-major] Facial Dermatoses / therapy. Keratosis, Actinic / therapy. Keratosis, Seborrheic / therapy. Rosacea / therapy

  • Genetic Alliance. consumer health - Keratosis, seborrheic.
  • MedlinePlus Health Information. consumer health - Rosacea.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19465852.001).
  • [ISSN] 1531-6998
  • [Journal-full-title] Current opinion in otolaryngology & head and neck surgery
  • [ISO-abbreviation] Curr Opin Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dermatologic Agents
  • [Number-of-references] 46
  •  go-up   go-down






Advertisement